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ABSTRACT 
Marybeth Anderson: Hexokinase 2 is important for tumor growth and metastasis in pancreatic 
ductal adenocarcinoma 
(Under the direction of Jen Jen Yeh) 
 
 Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer deaths in the 
United States. The majority of PDAC patients are diagnosed with metastatic disease, where 
treatment options are limited to cytotoxic chemotherapies that provide modest improvements in 
overall survival. Over 95% of PDAC tumors contain activating mutations in the oncogene KRAS, 
causing constitutive activation of key pathways promoting cancer cell proliferation, metabolism, 
and survival. Direct targeting of KRAS and its canonical effector pathways has proven 
ineffective for the treatment of advanced PDAC, suggesting that additional processes required 
for KRAS-driven tumorigenesis may be therapeutically beneficial. Metabolic reprogramming and 
increased glucose uptake were required for tumor growth in a genetically engineered mouse 
model of PDAC, suggesting that this pathway is important for PDAC tumorigenesis. 
We found the glycolytic enzyme hexokinase 2 (HK2) to be significantly upregulated in 
primary PDAC tumors and PDAC metastases. Increased expression of HK2 was associated with 
poor overall survival after curative surgery, suggesting that HK2 promotes aggressive tumor 
biology. HK2 was shown to be both necessary and sufficient for regulating glycolysis, primary 
tumor growth and metastasis of PDAC cell lines. Pharmacologic inhibition of lactate production 
abrogated HK2-driven invasion in PDAC cell lines, while addition of extracellular lactate 
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promoted invasion, suggesting that HK2 promotes metastasis by regulating glycolysis. Given 
this, direct inhibition of HK2 or lactate production may be a promising approach for the 
treatment of advanced PDAC.  
Because HK2 was a driver of PDAC tumor growth and metastasis, candidate microRNAs 
(miRNAs) were examined for their ability to function as tumor suppressors by inhibiting HK2 
expression. miR-148a and miR-216b were negatively correlated with HK2 and down regulated 
in PDAC tumors. Both miR-148a and miR-216b interacted with the 3’UTR of HK2 and inhibited 
HK2 expression in PDAC cell lines, suggesting that these miRNAs directly regulate HK2 in 
PDAC. Restoration of miR-148a and miR-216b expression mimicked the effects of HK2 
knockdown on anchorage independent growth and invasion of PDAC cell lines, suggesting a 
potential role for these miRNAs as inhibitors of PDAC tumor growth and metastasis via their 
regulation of HK2.  
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CHAPTER 1 : INTRODUCTION 
 
OVERVIEW OF PANCREATIC CANCER 
Clinical overview 
 Pancreatic cancer, 85% of which is pancreatic ductal adenocarcinoma (PDAC), is the 4th 
leading cause of cancer deaths in the United States. It is a devastating disease with an overall 
poor prognosis and a 5 year survival rate of around 7% (Howlader et al., 2013). Over half of all 
patients are initially diagnosed with metastatic disease, which greatly contributes to the high 
mortality observed in PDAC (Hidalgo, 2010). Significant risk factors for the development of this 
disease include a familial history of PDAC, a past medical history of chronic pancreatitis, long-
standing diabetes mellitus, and personal history of cigarette use (Hidalgo, 2010, Maitra and 
Hruban, 2008, Ryan et al., 2014). Inherited mutations such as those in tumor suppressors genes 
like p16 and BRCA1/2 account for a small percentage of PDAC patients but can significantly 
increase an individual’s lifetime risk of developing PDAC if present, suggesting that these tumor 
suppressors may be biologically important for tumor development (Maitra and Hruban, 2008).  
PDAC is considered a disease of the elderly, as it is rarely found in patients under the age 
of 45 and the median age at diagnosis is 71 years old (Howlader et al., 2013). Presenting 
symptoms depend upon the location and stage of the tumor at time of diagnosis (Hidalgo, 2010, 
Howlader et al., 2013, Ryan et al., 2014). Because 70% of tumors arise in the head of the 
pancreas and often cause obstruction of the common bile duct, a typical patient may present with 
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jaundice accompanied by nausea, vague abdominal pain, pancreatitis, and/or systemic symptoms 
such as weight loss (Bilimoria et al., 2007, Hidalgo, 2010, Ryan et al., 2014). Patients with 
tumors confined to the pancreas are eligible for curative surgery and have the highest rates of 
overall survival (Table 1-1, Hidalgo, 2010, Ryan et al., 2014). Unfortunately, only a small 
minority of PDAC patients are candidates for surgery and the majority present with unresectable 
or metastatic disease which have the worst overall survival rates (Table 1-1). Treatment of 
advanced PDAC is often palliative and limited to systemic chemotherapy with or without 
radiation therapy (Hidalgo, 2010). It is clear that treatment in advanced PDAC must to be 
improved, as the 5 year overall survival rate for patients with metastatic disease is <3% (Table 
1-1, Howlader et al., 2013).   
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TMN Staging Possible Treatment Prevalence 
Survival at 
5 years 
Stage IA 
T1 – Tumor localized within 
pancreas (<2cm diameter) 
N0 – No regional lymph 
node metastasis 
M0 - No distant metastases 
Curative surgery with 
adjuvant chemotherapy 
9% 27% 
Stage IB 
T2 – Tumor localized within 
pancreas (>2cm diameter) 
N0 
M0 
Stage IIA 
T3 – Tumor extends past 
pancreas without 
involvement of celiac axis or 
superior mesenteric artery 
N0 
M0 
Stage IIB 
T1, 2, 3 
N1 – Regional lymph node 
metastasis 
M0 
28% 10.7% 
Stage III 
T4 – Tumor involves celiac 
axis or the superior 
mesenteric artery 
N0 
M0 
Chemotherapy +/- 
radiation  therapy 
Stage IV 
T1, 2, 3 or 4 
N0, 1 
M1 – Distant metastases 
Palliative chemotherapy 53% 2% 
Table 1-1: Staging, treatment and survival of patients with PDAC.  
Staging according to the most recent edition of the American Joint Committee on Cancer 
tumor-node-metastasis classification and possible treatments adapted from Ryan, et al. 2014. 
T = primary tumor, N = regional lymph nodes, and M = metastasis. Prevalence and overall 
survival at 5 years adapted from SEER 18 data for all races and sexes (Howlader, et al. 2013).   
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Gemcitabine, a nucleoside analog, has been the standard of care for the treatment of 
metastatic PDAC since a 1997 clinical trial showed it improved overall survival of metastatic 
PDAC patients relative to the previous standard of care, 5-fluorouracil (5-FU, Burris et al., 
1997). Since 1997 multiple clinical trials have tested gemcitabine in combination with other 
cytotoxic or targeted chemotherapies in an attempt to improve outcomes for advanced PDAC 
patients. The vast majority of these trials produced modest, if any, improvements in overall 
survival until 2011 (Table 1-2).  In 2011 a large clinical trial showed a four drug regimen 
consisting of folinic acid (leucovorin), 5-FU, irinotecan, and oxaliplatin (FOLFIRINOX) to 
significantly improve survival of metastatic PDAC patients (11.1 months) when compared to 
treatment with gemcitabine alone (6.8 months, Conroy et al., 2011). Unfortunately, due to 
increased toxicities with the FOLFIRINOX regimen it can only be given to patients with a high 
performance status (Conroy et al., 2011). A 2013 trial showed that treatment with gemcitabine 
plus the cytostatic chemotherapy nab-paclitaxel improved overall survival of metastatic PDAC 
patients (8.5 months) when compared to gemcitabine alone (6.7 months, Von Hoff et al., 2013). 
This regimen was well tolerated and represents an alternative to FOLFIRINOX for the treatment 
of advanced PDAC (Von Hoff et al., 2013).  
While advancements in the treatment of metastatic PDAC have occurred in recent years, 
the improvements have been slow and incremental. With this in mind, much research has 
focused on understanding PDAC tumor biology. A better understanding of pathways required for 
tumor growth and metastasis will provide insight into pathways that can be targeted 
therapeutically for the treatment of advanced disease. 
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PDAC: an oncogenic KRAS driven cancer 
Over 90% of PDAC tumors contain activating mutations in the proto-oncogene kirsten 
rat sarcoma viral oncogene homolog (KRAS), which encodes for a small GTPase that regulates 
key signaling cascades responsible for cell growth, metabolism, and survival (Eser et al., 2014, 
Yeh and Der, 2007). More than 95% of KRAS mutations occur in codon 12 and ultimately impair 
the ability of KRAS to hydrolyze GTP, thus causing constitutive activation of key pathways 
 Total 
number of 
patients 
Treatment 
Median 
Survival 
(months) 
P-Value 
Burris, et al. 1997 126 
5-FU 
Gemcitabine 
4.4 
5.7 
0.002 
Herrmann, et al. 
2007 
319 
Gemcitabine 
Gemcitabine + capecitabine 
7.2 
8.4 
0.234 
Moore, et al. 2007 569 
Gemcitabine 
Gemcitabine + erlotinib 
5.9 
6.2 
0.038 
Kindler, et al. 2010 535 
Gemcitabine 
Gemcitabine + bevacizumab 
5.9 
5.8 
0.950 
Conroy, et al. 2011 342 
Gemcitabine 
FOLFIRINOX 
6.8 
11.1 
<0.001 
Von Hoff, et al. 
2013 
861 
Gemcitabine 
Gemcitabine + nab-paclitaxel 
6.7 
8.5 
<0.001 
Table 1-2: Clinical trials examining the efficacy of multi-drug regimens to gemcitabine 
alone for the treatment of advanced stage PDAC. 
Cytotoxic chemotherapies examined for the treatment of PDAC includes 5-FU, gemcitabine, 
capecitabine, and the FOLFIRINOX regimen (Conroy et al., 2011, Herrmann et al., 2007). 
Nab-paclitaxel consists of the cytostatic paclitaxel conjugated to albumin for efficient tumor 
delivery (Von Hoff et al., 2013). Erlotinib is a targeted therapy against the endothelial growth 
factor receptor (Moore et al., 2007) and bevacizumab is a targeted therapy targeted against the 
vascular endothelial growth factor-A (Kindler et al., 2010). 
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necessary for oncogenesis (Eser et al., 2014). Work in genetically engineered mouse models 
(GEMMs) showed that expression an oncogenic Kras allele (KrasG12D or KrasG12V) is sufficient 
to promote invasive PDAC over time (Guerra and Barbacid, 2013, Hingorani et al., 2003). 
Oncogenic Kras activity is also required for maintaining tumor growth in vivo, as its knockdown 
caused tumor regression in a PDAC GEMM (Ying et al., 2012). This is consistent with studies in 
human PDAC cell lines where genetic and pharmacologic inhibition of oncogenic KRAS activity 
was sufficient to inhibit cell growth (Collisson et al., 2011, Singh et al., 2009, Zimmermann et 
al., 2013).  
The requirement of oncogenic KRAS for tumor initiation and maintenance in preclinical 
models has led many to believe it represents an ideal target for therapy in PDAC. Two different 
approaches have been used to inhibit oncogenic KRAS signaling (Figure 1-1). The first approach 
involved direct inhibition of oncogenic KRAS with small molecule inhibitors that compete for 
nucleotide binding or modifying the interaction of oncogenic KRAS with effector or regulatory 
proteins (Cox et al., 2014, Yeh and Der, 2007). While these efforts resulted in the discovery of 
molecules that successfully bind oncogenic KRAS in vitro, they are unlikely to be useful in the 
clinic due to low-affinity binding of their target (Cox et al., 2014). A second approach focused 
on preventing the proper localization and function of oncogenic KRAS by inhibiting the post 
translational modifications necessary for the targeting of KRAS to the cell membrane (Cox et al., 
2014, Yeh and Der, 2007). One such class of drugs, farnesyltransferase inhibitors (FTIs), was 
tested in a phase III clinical trial for the treatment of advanced PDAC. Combination treatment 
with an FTI and gemcitabine ultimately showed no improvement in overall survival relative to 
gemcitabine alone, suggesting limited therapeutic benefit for this class of drugs in advanced 
PDAC (Van Cutsem et al., 2004).   
7 
 
Since efforts to directly target oncogenic KRAS have been unsuccessful, efforts have 
shifted to pharmacologic inhibition of canonical effector pathways upregulated by oncogenic 
KRAS signaling (Figure 1-1), including the phophoinositide-3-kinase (PI3K)/protein kinase B 
(PKB)/mammalian target of rapamycin (mTOR) pathway and the mitogen activated protein 
kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway (Cox et al., 2014, Eser et 
al., 2014). Targeting of these key effector pathways has been successful in preclinical mouse 
models of PDAC (Alagesan et al., 2014, Eser et al., 2013), prompting the clinical evaluation of 
drugs targeted against PI3K/PKB/mTOR and MAPK/ERK signaling (Figure 1-1, Cox et al., 
2014, Eser et al., 2014). Unfortunately, phase II studies with inhibitors of mTOR, temsirolimus 
and everolimus, showed no anti-tumor activity in patients with metastatic PDAC (Javle et al., 
2009), suggesting that these therapies are not clinically useful and other mechanisms to inhibit 
PI3K signaling should be clinically examined in PDAC. A phase II clinical trial with the oral 
MAPK/ERK kinase (MEK) inhibitor CI-1040 showed that the therapy did not have significant 
anti-tumor activity in PDAC, as none of the 15 patients examined exhibited a complete or partial 
response with MEK inhibitor treatment (Rinehart et al., 2004), suggesting that inhibition of the 
MAPK/ERK signaling pathway with CI-1040 is not clinically important and other inhibitors 
should be examined for their ability to improve outcomes in advanced PDAC.   
While efforts to target canonical KRAS effector signaling have been unsuccessful thus 
far, studies examining the efficacy of additional pharmacologic inhibitors targeted against these 
pathways are still ongoing.  
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KRAS and molecular subtypes of PDAC 
One hypothesis for the lack of clinical response to inhibition of canonical KRAS effector 
signaling is that PDAC is more genetically diverse disease than originally thought. Exome 
 
 
Figure 1-1: Inhibition of oncogenic KRAS signaling for the treatment of advanced 
PDAC.  
Activating mutations in the KRAS result in a constitutively active KRAS protein bound to 
GTP. Oncogenic KRAS promotes PDAC cell growth and survival through activation of well 
characterized effector pathways including the ERK MAPK (purple) and PI3K/PKB/mTOR 
(orange) pathways. Efforts to inhibit KRAS signaling in cancer have focused on inhibiting 
KRAS itself, its membrane localization, and its downstream effector pathways, all of which 
have produced suboptimal results, suggesting that future efforts should focus on targeting 
non-canonical KRAS effector signaling. 
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sequencing of 109 PDAC tumors showed that in addition to oncogenic KRAS mutations, many 
tumors contain mutations in pathways important for tumorigenesis, including transforming 
growth factor-β signaling, transcriptional regulation, DNA repair, and stem cell signaling, which 
are not directly involved in KRAS effector signaling (Witkiewicz et al., 2015). Some of these 
mutations have targeted therapies currently in clinical trials and, therefore, represent novel 
targets for the treatment of advanced PDAC (Witkiewicz et al., 2015). The promise of targeting 
these additional mutations in PDAC is exciting and may help the field move away from the use 
of systemic cytotoxic chemotherapies toward a more targeted approach.  
Further demonstrating the clinical importance of molecular diversity within PDAC are 
studies which examined gene expression of primary PDAC tumors to identify two molecularly 
distinct subtypes of PDAC, classical and quasi-mesenchymal (QM, (Collisson et al., 2011). The 
classical subtype exhibited gene expression profiles consistent with epithelial cells and predicted 
better overall survival in PDAC patients undergoing curative surgery, while the QM subtype 
exhibited high expression of mesenchymal genes and had worse overall survival (Collisson et al., 
2011). The poor overall observed in the QM subtype suggests that this subtype represented 
tumors with an aggressive biology. Consistent with this, QM PDAC cell lines were resistant to 
genetic inhibition of oncogenic KRAS while classical subtypes were sensitive to KRAS 
inhibition (Collisson et al., 2011).  
A panel of PDAC and non-small cell lung cancer (NSCLC) cell lines resistant to 
inhibition of oncogenic KRAS were observed to have gene expression profiles similar to the QM 
PDAC subtype and consistent with an epithelial to mesenchymal transition (EMT, Singh et al., 
2009). EMT is a process associated with aggressive tumor biology and drives metastasis in 
cancer (Singh et al., 2009). PDAC and NSCLC cell lines resistant to oncogenic KRAS inhibition 
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were found to be sensitive to pharmacologic inhibition of SYK, a protein kinase upregulated in 
these cell lines and known to be important for EMT (Hong et al., 2014, Singh et al., 2009), 
suggesting that inhibition of pathways outside of canonical KRAS effector signaling may be 
important for treatment of the clinically aggressive QM PDAC subtype. This study further 
emphasizes the importance of understanding the molecular and genetic diversity within PDAC 
because these may dictate response to therapy. 
While it is known that KRAS signaling drives tumorigenesis, it is clear from studies 
investigating genetic and molecular diversity of PDAC that pathways outside of canonical KRAS 
signaling are important for disease progression. Preclinical efforts should, therefore, focus on 
investigating novel pathways important for oncogenic KRAS tumor growth and how these 
pathways influence growth and survival of the multiple PDAC subtypes.  
 
REGULATION OF GLUCOSE METABOLISM IN PDAC 
Metabolic reprogramming in PDAC 
In an effort to identify additional pathways important for promoting tumor growth in 
PDAC, a doxycycline inducible Kras driven mouse model of PDAC was used to examine the 
biological effects of oncogenic Kras activity (Ying et al., 2012). The authors first showed a 
requirement of oncogenic Kras for tumor maintenance, as inhibition of Kras expression caused 
tumor regression (Ying et al., 2012). Gene expression analysis and liquid chromatography-
tandem mass spectrometry of PDAC tumors and cell lines after 24 hours of Kras inactivation 
showed down regulation of genes involved with glucose metabolism and decreased accumulation 
of glycolytic intermediates (Ying et al., 2012). Oncogenic Kras regulated transcription in this 
model by activation of MAPK/ERK signaling pathway, which led to increased activity of the c-
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MYC transcription factor (Figure 1-2 (Ying et al., 2012). In the presence of oncogenic Kras, 
glycolytic intermediates were shuttled into anabolic pathways, including hexosamine 
biosynthesis and the pentose phosphate pathway, that are required for tumor growth in vitro and 
in vivo (Ying et al., 2012), suggesting that targeting of these individual biosynthetic pathways 
may be clinically important.  
 
 
 
 
 
Figure 1-2: Oncogenic KRAS activity promotes transcriptional upregulation of genes 
required for elevated rates of glucose metabolism and tumor growth in vivo. 
Activation of oncogenic KRAS causes transcriptional upregulation in a c-MYC dependent 
manner of key regulatory genes involved with anabolic glucose metabolism (shown in bold, 
right panel, (Ying et al., 2012). Genetic inhibition of GFPT1, regulating hexosamine 
biosynthesis, and RPE and RPIA, regulating the pentose phosphate pathway, is sufficient to 
inhibit growth, suggesting that targeting these pathways would be beneficial for the treatment 
of PDAC (Ying et al., 2012). GLUT1 and HK2 are required for glucose uptake (Glucose = 
GLU, orange) and are upstream of these important biosynthetic pathways required for 
oncogenesis. 
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To examine differences in glucose metabolism among the classical and QM PDAC   
subtypes, levels of metabolites in media collected during logarithmic growth across a panel of 38 
PDAC cell lines were collected (Daemen et al., 2015). Media collected from classical cell lines 
was enriched with lipid metabolites, suggesting an increased rate of lipid synthesis, while media 
collected from QM cells was enriched with glycolytic intermediates and metabolites regulating 
redox potential (Daemen et al., 2015). Carbon isotope labeling showed that classical cell lines 
utilized glucose for lipid synthesis while QM utilized glucose for aerobic glycolysis (Daemen et 
al., 2015). Differences in metabolic demands between the PDAC subtypes suggested that they 
would respond differently to metabolic inhibitors. Indeed classical cell lines were sensitive to 
inhibitors of lipid synthesis while QM cell lines were sensitive to inhibitors of glycolysis, such as 
the pyruvate analog oxamate and a direct inhibitor of lactate dehydrogenase A (LDHA), further 
emphasizing the need to design therapies targeted against a genetically diverse PDAC with 
multiple subtypes (Figure 1-3, (Daemen et al., 2015).  
These studies outline an important role for targeting glucose metabolism in PDAC, as 
multiple biosynthetic pathways, including glycolysis, lipid synthesis, and the pentose phosphate 
pathway, are required for growth in preclinical models of PDAC. The different subtypes of 
PDAC utilize glucose for different biosynthetic processes, emphasizing the importance of 
understanding the biological differences between the molecular subtypes. Direct inhibition of 
glucose uptake may prove to be an efficient way to treat both molecular PDAC subtypes, as it 
will impede the flow of glucose into pathway necessary for growth in one step (Figure 1-2).  
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Tumor specific regulators of glucose uptake 
Oncogenic Kras transcriptionally upregulates multiple proteins required for glucose 
metabolism, including glucose transporter 1 (Glut1) and hexokinase 2 (Hk2) (Ying et al., 2012). 
Each of these proteins is required for glucose uptake and represents attractive targets for therapy 
because they can limit the flow of glucose into multiple pathways required for cancer cell growth 
and survival (Figure 1-2). GLUT1 belongs to a family of transmembrane proteins consisting of 
13 different isoforms that are responsible for glucose entry and exit into the cell (Wood and 
Trayhurn, 2003). GLUT1 is expressed in many tissues throughout the body, but it is most highly 
expressed in erythrocytes and the endothelial cells making up the blood brain barrier (Wood and 
 
Figure 1-3: Summary of the distinct molecular subtypes that exist within PDAC patient 
tumors and cell lines. 
PDAC subtypes were previously defined by Collisson et al (2011), while studies evaluating 
glucose metabolism in each subtype were performed by Daemen et al (2015).  
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Trayhurn, 2003). GLUT1 is often upregulated in cancer cells and its transcription is stimulated 
by low glucose, hypoxia, and oncogenes such as KRAS, ERBB2, and c-MYC (Macheda et al., 
2005, Natsuizaka et al., 2007). The upregulation of GLUT1 in cancer suggests that it may be a 
good target for therapy, however its widespread expression in tissues throughout the body 
suggest that systemic GLUT1 inhibition may cause off-target effects in non-cancerous tissue.  
 HK2 belongs to a family of 4 proteins that are responsible for phosphorylation of 
glucose, a reaction necessary for keeping glucose in the cell and promoting its flow into 
downstream metabolic pathways (Wilson, 2003). HK2 is expressed at high levels during 
development but limited to skeletal muscle and fat in adult tissue (Vogt et al., 2000). HK2 is 
thought to be the “cancer-specific” hexokinase isoform as it is the main isoform upregulated in 
highly glycolytically active cancers (Katabi et al., 1999, Smith, 2000). This is observed in 
preclinical mouse models which show specific upregulation of Hk2, and not Hk1, in NSCLC and 
breast cancer GEMMs (Patra et al., 2013). Analysis of patient tissue also showed HK2, and not 
other isoforms, to be upregulated in tumors relative to normal tissue (Hamabe et al., 2014, 
Ogawa et al., 2015, Palmieri et al., 2009, Peng et al., 2008).  
HK2 may be preferentially upregulated in cancer cells because it has a high affinity for 
glucose and, unlike HK1, it is not sensitive to inhibition with glucose-6-phosphate (Robey and 
Hay, 2006).  In addition, HK2 is upregulated under environmental conditions commonly 
observed in solid tumors, including low glucose and hypoxia (Natsuizaka et al., 2007, Riddle et 
al., 2000, Zhao et al., 2011). The cancer specific expression of HK2 and its important role in 
regulation of glucose metabolism make it an attractive target for the treatment of glycolytically 
active cancers such as PDAC. 
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HK2: an important regulator of cancer cell growth and glucose metabolism 
 To determine if Hk2 is required for tumor growth in vivo, a recent study used GEMMs of 
NSCLC and breast cancer. Genetic deletion of Hk2 resulted in decreased tumor growth and 
increased overall survival of both GEMMs (Patra et al., 2013). HK2 is required for tumor growth 
of multiple cancer types, as its genetic inhibition resulted in decreased growth of cancer cell lines 
in vitro and in vivo (Gershon et al., 2013, Jiang et al., 2012, Wolf et al., 2011, Yoshino et al., 
2013). The inhibitory effect of HK2 knockdown on tumor growth in these models is likely due to 
decreased glucose metabolism, as genetic inhibition of Hk2 in Kras and ErbB-2 mutant cells was 
sufficient to inhibit the flow of glucose into the pentose phosphate pathway and the citric acid 
cycle (Patra et al., 2013), supporting a role for the targeting of HK2 in PDAC as it has known 
that anabolic glucose metabolism is required for tumor growth in vivo (Ying et al., 2012). To 
examine the feasibility of targeting HK2 in the clinic, the effects of HK2 inhibition in normal 
tissue must be examined to ensure that systemic delivery of a potential HK2 inhibitor would not 
cause overwhelming toxicity. Genetic knockdown of Hk2 in the normal tissue of adult mice did 
not decrease overall survival, had no effect on body weight or growth, and had no effect on 
systemic glucose tolerance (Patra et al., 2013), suggesting that systemic targeting of HK2 would 
be well tolerated by patients. Even though HK2 has been shown to be required for tumor growth 
of multiple cancers, its role in promoting tumor growth in PDAC has yet to be established.   
 
MICRO RNA REGULATION OF HK2 
HK2 expression is upregulated in multiple cancer types and its function is important for 
tumor growth in preclinical models of cancer (Gershon et al., 2013, Patra et al., 2013, Wolf et al., 
2011). While previous studies have shown HK2 to be upregulated in an oncogenic Kras 
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dependent manner, other mechanisms regulating HK2 expression may be important for driving 
oncogenesis. microRNAs (miRNAs) are short, noncoding RNA molecules which function as 
negative regulators of gene expression (Bartel and Chen, 2004). These endogenously expressed, 
single stranded RNA molecules bind to the 3’ untranslated region (3’UTR) of target mRNA 
molecules in a sequence dependent manner (Huntzinger and Izaurralde, 2011). The interaction 
between a miRNA and its target mRNA result in recruitment of proteins required for mRNA 
degradation or inhibition of translation, an interaction that ultimately causes decreased target 
protein expression (Kim and Kim, 2012).  
Since their discovery in the 1990s miRNAs have garnered much interest in the field of 
cancer research, because these molecules are commonly dysregulated in tumors and are 
regulators of a variety of biological processes, including glucose metabolism (Ruan et al., 2009, 
Singh et al., 2012). miRNAs are known to regulate HK2 expression in a variety of cancers (Fang 
et al., 2012, Jiang et al., 2012, Yoshino et al., 2013). In a GEMM of lung cancer, miR-143 was 
shown to be downregulated in Kras mutant tumors and was inversely correlated with HK2 
expression (Fang et al., 2012). Restoration of miR-143 expression successfully inhibited aerobic 
glycolysis and tumor growth in colon, lung and renal cell carcinoma cell lines, suggesting that 
miRNA regulation of HK2 is important for suppressing tumor growth (Fang et al., 2012, Jiang et 
al., 2012, Yoshino et al., 2013). There are currently no direct inhibitors of HK2 available for use 
in the clinic and pharmacologic inhibition of HK2 will likely be difficult to achieve because of 
similarities in affinity for glucose and protein sequence between hexokinase isoforms (Robey 
and Hay, 2006, Wilson, 2003). miRNAs may, therefore, represent a unique opportunity to inhibit 
HK2 in the clinic. While miRNA regulation of HK2 in PDAC has not been studied, but existing 
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literature suggests that this interaction may be important for PDAC tumorigenesis and could be a 
useful mechanism for clinical inhibition of HK2.  
 
CONCLUSIONS AND DISSERTATION GOALS 
Does HK2 promote tumor growth in PDAC? 
PDAC is a highly lethal disease with an overall poor prognosis (Ryan et al., 2014). Over 
half of all patients present to the clinic with existing metastatic disease, suggesting that PDAC 
tumors are biologically aggressive (Ryan et al., 2014). While 90% of patient tumors contain 
activating mutations in the oncogene KRAS, direct targeting of this gene and its downstream 
effector pathways was ineffective for the treatment of advanced PDAC, suggesting a need to 
target non-canonical KRAS signaling pathways in the clinic (Cox et al., 2014, Eser et al., 2014). 
Glucose metabolism was required for tumor maintenance in a preclinical model of PDAC and 
inhibition of key enzymes regulating biosynthetic pathways downstream of glucose uptake 
caused decreased tumor growth, suggesting that targeting glucose metabolism would be 
beneficial in PDAC (Ying et al., 2012). At least two biologically distinct subtypes of PDAC exist 
and these subtypes utilize glucose in different ways (Collisson et al., 2011, Daemen et al., 2015). 
Because of this, the most promising and efficient method for the treatment of molecularly 
diverse PDAC would include direct targeting of glucose uptake and, therefore, preventing its 
diversion into multiple downstream pathways required for growth.  
HK2 has been shown to be important for glucose metabolism in preclinical models of 
Kras driven lung cancer (Patra et al., 2013) and we hypothesize that it is essential for tumor 
growth in PDAC. The studies outlined in chapter 2 examined the requirement of HK2 for PDAC 
disease progression. Analysis of gene expression in PDAC patient tumors suggested that HK2 
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may be required for both primary tumor growth and metastasis in PDAC. We used in vitro and in 
vivo techniques to show that HK2 is both necessary and sufficient to promote PDAC tumor and 
metastasis. The ability of HK2 to promote invasion of PDAC cell lines was dependent upon 
glycolysis, suggesting a direct link between elevated rates of glycolysis and increased metastatic 
potential in PDAC. 
 
Can miRNAs regulate tumor growth in PDAC by inhibiting HK2 expression? 
miRNAs are important regulators of gene expression and glucose metabolism in PDAC 
(Singh et al., 2012). These short, single stranded non-coding RNA molecules are dysregulated in 
PDAC tumors (Price and Chen, 2014) and may participate in tumorigenesis by regulating 
metabolic genes essential for tumor growth, such as HK2. The studies outlined in chapter 3 
aimed to identify novel candidate miRNAs that may regulate HK2 in PDAC. Twenty four 
miRNAs were shown to be inversely correlated with HK2 expression, down regulated in PDAC 
tumors, and predicted to bind the 3’UTR of HK2. Two candidate miRNAs, miR-148a and miR-
216b, directly interacted with the 3’UTR of HK2 and inhibited HK2 expression in PDAC cell 
lines. Overexpression of miR-148a and miR-216b mimicked the effect of HK2 knockdown on 
PDAC anchorage independent growth and invasion, suggesting that these miRNAs may function 
as tumor suppressors in PDAC.  
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CHAPTER 2 : HEXOKINASE 2 PROMOTES TUMOR GROWTH AND METASATSIS 
BY REGULATING LACTATE PRODUCTION IN PANCREATIC CANCER1 
 
INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a five-year 
overall survival of around 7% (Howlader et al., 2013). Over half of all patients initially present 
with metastatic disease, where treatment options are limited to cytotoxic chemotherapies that are 
not well tolerated and provide modest improvements in overall survival (Ryan et al., 2014). Over 
90% of PDAC tumors contain activating mutations in the oncogene KRAS, suggesting that it may 
be an ideal target for therapy (Yeh and Der, 2007). While knockdown of KRAS inhibits PDAC 
cell growth in vitro, direct targeting of KRAS and its main effector pathways have proven 
unsuccessful in the clinic (Bryant et al., 2014, Yeh and Der, 2007). Much work has focused on 
identifying additional pathways promoting KRAS driven tumor growth in PDAC, with the hope 
of identifying new targets for therapy. 
The importance of glucose metabolism in KRAS driven oncogenesis is well recognized 
(Blum and Kloog, 2014, Bryant et al., 2014, Guillaumond et al., 2014, Zhao et al., 2011). In a 
                                                 
1  This chapter is adapted from a research article submitted for publication in the journal 
Oncotarget. The concept of the project was developed by myself and Jen Jen Yeh. I performed 
the in vitro experiments, while Raoud Marayati and the Animal Studies Core Facility at the 
University of North Carolina assisted with in vivo experiments. RNA sequencing data was 
processed by Richard Moffitt. Jen Jen Yeh and I prepared the manuscript for publication.  
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genetically engineered mouse model (GEMM) of PDAC, oncogenic Kras activity promoted 
transcriptional upregulation of key enzymes involved in glucose processing, including those 
regulating glycolysis, hexosamine biosynthesis and the pentose phosphate pathway (Ying et al., 
2012). Activity of these enzymes was required for tumor growth, suggesting a role for targeting 
glucose uptake and anabolism in PDAC (Ying et al., 2012). Hexokinase 2 (HK2) is an enzyme 
responsible for phosphorylating glucose, a reaction necessary for glucose processing (Deeb et al., 
1993, Wilson, 2003). Four hexokinase isoforms (HK1-HK4) are expressed at varying levels in 
tissues, but HK2 is the sole isoform overexpressed in cancer (Katabi et al., 1999, Mathupala et 
al., 2006, Mathupala et al., 2009, Patra et al., 2013, Smith, 2000). Genetic deletion of Hk2 caused 
a decrease in tumor burden and increased overall survival of Kras-driven lung and ErbB2-driven 
breast cancer GEMMS (Patra et al., 2013). In addition, HK2 knockdown has been found to 
successfully inhibit tumor growth in glioblastoma, medulloblastoma and renal cell carcinoma 
(Gershon et al., Wolf et al., 2011, Yoshino et al., 2013).  
While a direct role for HK2 in PDAC has yet to be reported, studies examining gene 
expression and PDAC patient outcomes have shown an association between increased expression 
of HK2 and more aggressive disease (Chaika et al., 2012, Ogawa et al., 2015). Anabolic glucose 
metabolism promoted disease progression in a PDAC GEMM, however analysis of human tissue 
revealed increased expression of genes involved in aerobic glycolysis, including HK2, in primary 
PDAC and PDAC metastases without changes in expression of anabolic genes, suggesting that 
glycolysis may be important in human disease (Chaika et al., 2012). PDAC cell lines with 
elevated rates of glycolysis showed increase expression of an epithelial-mesenchymal transition 
(EMT) gene signature and were classified as a quasi-mesenchymal, a PDAC subtype previously 
associated with shorter overall survival (Cheng et al., 2013, Collisson et al., 2011, Daemen et al., 
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2015). Taken together these studies provide strong, indirect evidence suggesting a role for HK2 
and glycolysis in promoting PDAC disease progression. 
The current study shows that HK2 is required for primary tumor growth and metastasis in 
PDAC. By overexpressing HK2 in PDAC cell lines, we show that increased levels of HK2 are 
sufficient to promote cell proliferation, anchorage independent growth (AIG) and invasion, 
supporting a role for HK2 in driving disease progression. Pharmacologic inhibition of lactate 
production dampens the effects of HK2 on invasion while increased extracellular lactate is 
sufficient to promote invasion. Overall, this study provides a mechanistic link between HK2 and 
metastasis via regulation of lactate production and suggests that direct inhibition of HK2 may be 
a promising approach for treating PDAC.  
 
RESULTS 
Genes involved in glucose uptake and glycolysis are dysregulated in PDAC 
We examined the expression of genes involved with glucose metabolism using a 
previously described dataset of tumors from primary and metastatic sites of 143 PDAC patients 
(GSE 71729) (Moffitt et al., 2015). A list of 153 unique genes of interest was compiled using 
existing KEGG and Reactome gene lists for glucose metabolism, glycolysis and 
gluconeogenesis, the pentose phosphate pathway and O-glycan biosynthesis (Subramanian et al., 
2005). Also included were 14 genes belonging to the family of sugar transport facilitators 
(SLC2A/GLUT) that are responsible for glucose uptake (Joost et al., 2002, Wood and Trayhurn, 
2003). To identify genes associated with tumorigenesis, we looked for those highly expressed in 
primary tumors compared to unmatched normal pancreas. To identify genes associated with 
metastasis, we looked for genes highly expressed in metastases compared to primary tumors.  
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Four genes – glucose transporter 1 (GLUT1), HK2, lactate dehydrogenase A (LDHA), 
and triosephosphate isomerase 1 (TPI1) – were upregulated in primary tumors compared to 
normal pancreas and in metastases compared to primary tumors (P<0.001, Figure 2-1). GLUT1 
and HK2 both play a role in glucose uptake. LDHA is a key enzyme responsible for producing 
lactate from pyruvate, the final step in aerobic glycolysis (Adeva et al., 2013, Hsu and Sabatini, 
2008). GLUT1, HK2, and LDHA were previously found to be regulated in an oncogenic Kras 
dependent manner, suggesting that they may be important for KRAS-driven tumor growth (Ying 
et al., 2012). TPI1 catalyzes an isomerization reaction in the glycolytic cascade but is not 
regulated in a Kras-dependent manner and was, therefore, not further studied (Ying et al., 2012). 
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Figure 2-1: HK2 (a), GLUT1 (b), LDHA (c) and TPI1 (d) are upregulated in PDAC 
primary tumors and metastases relative to normal pancreas.  
Log2 of gene expression in normal pancreas, primary PDAC, and PDAC metastases. Box 
shows median expression with upper and lower quartiles and whiskers show maximum and 
minimum values. A one-way ANOVA with Bonferroni correction for multiple comparisons 
test determined statistical significance.   
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Increased HK2 expression is associated with poor patient survival after surgery 
Increasing expression of key enzymes regulating glucose uptake and glycolysis in 
primary tumors and metastases suggest that these pathways are associated with aggressive tumor 
biology. To determine if GLUT1, LDHA, or HK2 was associated with clinical outcome, we 
evaluated the relationship between gene expression and patient survival. Patients with tumors 
containing high HK2 expression had a median survival of 13 months while patients with tumors 
containing low HK2 expression had a median survival of 21 months (P=0.027, Figure 2-2a). 
HK2 was also associated with shorter overall survival in patients with localized tumors who 
underwent curative surgery (hazard ratio (HR) 1.31 (1.07, 1.60), Figure 2-2b), suggesting that 
high HK2 expression may be associated with early disease relapse and metastasis. Neither 
GLUT1 nor LDHA expression was associated with patient survival (Figure 2-2b).  
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HK2 is necessary for AIG and invasion in PDAC cell lines  
  To directly assess the requirement of HK2 for promoting tumor growth and invasion, si- 
and shRNA were used to transiently and stably knockdown HK2 in two PDAC cell lines, 
CFPAC-1-LUC and PANC-1 (Figure 2-3). Both lines contain activating mutations in KRAS and 
exhibit the highest levels of HK2 expression relative to the normal immortalized epithelial cell 
 
Figure 2-2: HK2 expression is associated with poor overall survival.  
(a) Groups for Kaplan Meier survival analysis were based off HK2 expression in primary 
tumors. Lowest quartile showed median survival of 24 months (95% CI [14 ,34]) while 
highest quartile showed median survival of 10 months (95% CI [9, 11]).  
(b) Correlation between HK2, GLUT1 and LDHA expression in primary tumors (n=125) and 
overall survival as determined by univariate Cox proportional regression. Hazard ratios and 
95% CI shown. 
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line HPNE across a panel of PDAC cell lines (P<0.001, Figure 2-4). Levels of HK1 were 
unaffected by transient and stable knockdown of HK2, suggesting that our constructs were HK2 
specific and that there was no compensatory increase in HK1 expression (Figure 2-3).  
To examine the effect of HK2 knockdown on PDAC cell growth, a soft agar assay was 
used to assess for AIG, a phenotype associated with both tumor growth and metastatic potential 
(Mori et al., 2009). Transient knockdown of HK2 in the CFPAC-1-LUC cell line caused a 72.7% 
decrease in colony growth compared to that observed for the nonspecific (NS) control (P<0.001, 
Figure 2-5b). Similar findings were observed with stable knockdown of HK2 (P<0.030, Figure 
2-5b). Transient and stable knockdown in PANC-1 with siHK2 and shHK2#1 resulted in an 
82.0% and 71.0% decrease in colony growth relative to NS, respectively (P<0.001, Figure 2-5b). 
Stable knockdown using shHK2#2 caused 30.1% growth inhibition relative to shNS (P=0.06, 
Figure 2-5b). The dampened effect on colony growth may be explained by inefficient 
knockdown of HK2 with the shHK2#2 construct (Figure 2-3). To assess the effect of HK2 
knockdown on invasion, a Matrigel coated transwell invasion assay was used (Figure 2-6a). 
Transient and stable knockdown of HK2 caused an approximate 50% decrease in invasion in 
both cell lines (P<0.030, Figure 2-6b).  These results show that HK2 is required for PDAC AIG 
and invasion. 
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Figure 2-3: Transient and stable knockdown of HK2 expression in PDAC cell lines. 
Transient and stable knockdown of HK2 was achieved using siRNA (siHK2, 20 nM) and a 
doxycycline inducible lentiviral shRNA construct (shHK2# and #2) in CFPAC-1-LUC (a) and 
PANC-1 (b) cell lines. Cells were isolated for western blot or phenotypic assay after 72 hours 
of doxycycline (2 µg/mL) exposure. 
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Figure 2-4: HK2 is upregulated in PDAC cell lines relative to the normal immortalized 
pancreatic epithelial cell line HPNE. 
Fold change in HK2 expression across a panel of PDAC cell lines relative to the immortalized 
epithelial cell line HPNE. Fold change determined using the ΔΔCT method with mean and 
standard error of the mean (SEM) shown (n=3 technical replicates). 
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Figure 2-5: HK2 is required for AIG of PDAC cell lines. 
(a) Representative images of colony formation in soft agar assays.  
(b) Percent of growth with HK2 knockdown relative to control (siNS or shNS). Mean ± SEM 
of biological replicates shown (n=4).  
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Figure 2-6: HK2 is required for invasion of PDAC cell lines through a reconstituted 
matrix.  
(a) Representative images of colony formation in soft agar assays.  
(b) Percent of invasion with HK2 knockdown relative to control (siNS or shNS). Average ± 
SEM for six biological replicates is shown.  
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HK2 is sufficient to promote AIG and invasion in PDAC cell lines  
 HK2 expression is limited in most normal tissues but preferentially upregulated in cancer 
cells (Katabi et al., 1999). Whether HK2 is sufficient to promote PDAC growth and metastasis 
remains unknown. To examine this, two PDAC cell lines stably overexpressing HK2 cDNA 
were generated (CFPAC-1-HK2 and PANC-1-HK2, Figure 2-7a). Hexokinase (HK) activity was 
measured to confirm that stable HK2 overexpression resulted in increased protein function. A 
3.3-fold increase in HK activity was observed in CFPAC-1-HK2 and a 1.4-fold increase was 
observed for PANC-1-HK2 (P<0.001, Figure 2-7b). Additionally transient knockdown of HK2 
with siRNA caused a significant decrease in HK when compared to the control (P<0.010, Figure 
2-7b). No change in HK1 expression was found in the cell lines generated, suggesting that the 
increased HK activity can be solely attributed to changes in the level of HK2. 
We next determined the effects of HK2 overexpression on AIG and invasion. A 5.1-fold 
increase in colony growth was observed with stable HK2 overexpression relative to the GFP 
control in CFPAC-1-HK2, while a 1.7-fold increase was observed in PANC-1-HK2 (P=0.020, 
Figure 2-8).  We hypothesized that this increase in AIG results from an increased rate of cell 
proliferation, as HK2 overexpression caused an increase in anchorage dependent growth as well 
as AIG (Figure 2-8a). A 3.4-fold increase in invasion was observed for CFPAC-1-HK2 relative 
to the control while a 2.4-fold increase was observed for PANC-1-HK2 (P<0.002, Figure 2-9). 
Our data suggests that increased HK2 expression is sufficient to promote anchorage dependent 
and independent growth, as well as invasion.  
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Figure 2-7: Altered HK2 expression and activity in PDAC cell lines. 
(a) Stable overexpression of HK2 (pHAGE HK2) relative to control (pHAGE GFP) in 
CFPAC-1 and PANC-1 cell lines.  
(b) Percent hexokinase activity of knockdown (siNS vs. siHK2) and overexpression (pHAGE 
GFP vs. pHAGE HK2) cell lines relative to control. Mean ± SEM of biological replicates 
(n=3) shown with student’s t-tests for statistical significance.  
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Figure 2-8: HK2 is sufficient to promote AIG and cell proliferation in PDAC cell lines. 
(a) Cell proliferation in CFPAC-1-GFP and CFPAC-1-HK2 as determined using a MTT 
assay. Mean ± SEM of technical replicates (n=4) shown with student’s t-tests for statistical 
significance at 48, 72, and 96 hours of growth.  
(b) Percent colony growth with HK2 overexpression relative to control. Mean ± SEM of 
biological replicates (n=3) shown with student’s t-tests for statistical significance. 
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HK2 promotes invasion by regulating lactate production 
 We hypothesized that the HK2-driven changes in invasion observed result from changes 
in glycolysis, as elevated glycolysis has been previously linked to metastasis (Collisson et al., 
2011, Daemen et al., 2015). To this end, we measured lactate production in cell lines with 
transient knockdown and stable overexpression of HK2. An approximate 20% decrease in lactate 
production was observed with HK2 knockdown relative to the NS control (P<0.003, Figure 
2-10). Conversely, stable HK2 overexpression produced a 1.3-fold and 1.2-fold increase in 
lactate production for the CFPAC-1-HK2 and PANC-1-HK2 cell lines, respectively, suggesting 
that changes in HK2 are sufficient to alter glycolysis in PDAC cell lines (P<0.003, Figure 2-10). 
To determine if HK2 promotes invasion in a lactate dependent manner, the pharmacologic 
 
Figure 2-9: HK2 overexpression is sufficient to promote invasion of PDAC cell lines. 
Percent invasion with HK2 overexpression relative to GFP control. Mean ± SEM of 
biological replicates (n=6) shown with student’s t-tests for statistical significance.  
 
35 
 
inhibitor oxamate was used to inhibit glycolysis in cells with stable HK2 overexpression. Cells 
were pretreated with oxamate at the calculated IC50 prior to seeding into transwell invasion 
assay (Figure 2-11a). At the time of seeding, a 3.2 and 4.1-fold decrease in lactate production 
was observed with oxamate treatment relative in CFPAC-1-HK2 and PANC-1-HK2, 
respectively, confirming inhibition of glycolysis relative to control (P<0.001, Figure 2-11b).  
An approximate 2.0-fold decrease in invasion was observed in oxamate treated cells with 
stable expression of HK2, suggesting that glycolysis is required for HK2 to promote invasion 
(P<0.010, Figure 2-11c). We next determined if the addition of extracellular lactate was 
sufficient to promote invasion. Cells were incubated with media supplemented with lactate (40 
mM) for 24 hours, conditions that induce changes in histone acetylation and gene expression 
(Latham et al., 2012). The addition of lactate was sufficient to promote invasion in both cell 
lines, as a 3.5-fold increase in invasion for CFPAC-1-HK2 and 2.5-fold increase in invasion of 
PANC-1-HK2 were observed (P<0.001, Figure 2-12). These results suggest that HK2 regulates 
invasion in a lactate-dependent manner, supporting a direct link between elevated rates of 
glycolysis and increased metastatic potential.  
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Figure 2-10: HK2 regulates lactate production in PDAC cell lines. 
Relative lactate production in CFPAC-1 and PANC-1 with HK2 knockdown (siHK2 vs. siNS) 
and overexpression (pHAGE HK2 vs. pHAGE GFP). Mean ± SEM of biological replicates 
(n=3) shown with student’s t-tests for statistical significance. 
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Figure 2-11: The pyruvate analog oxamate inhibits lactate production and HK2 driven 
invasion of PDAC cell lines. 
(a) IC50 determination for CFPAC-1-HK2 and PANC-1-HK2 after 72 hours of oxamate 
treatment; Mean ± SEM of technical replicates (n=4) shown with student’s t-tests for 
statistical significance. CFAPC-1 IC50 calculated to be 15 mM while PANC-1 determined to 
be 16mM using GraphPad Prism software (v.5, GraphPad Software, INC. La Jolla, CA, 
USA). (b) L-lactate produced (mM) in CFPAC-1-HK2 and PANC-1-HK2 cell lines treated 
with PBS or IC50 oxamate for 72 hours. Mean ± SEM of biological replicates (n=3) shown 
with student’s t-tests for statistical significance. (c) Percent invasion in cells treated with PBS 
or IC50 oxamate. Mean ± SEM of biological replicates (n=6) shown with student’s t-tests for 
statistical significance.  
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HK2 is necessary for PDAC tumor growth and influences gene expression 
To examine the effects of HK2 knockdown on primary tumor growth, CFPAC-1-LUC 
cells containing a doxycycline-inducible shHK2#1 or shNS (control) were subcutaneously 
injected into immune-compromised mice. HK2 knockdown was confirmed in tumors expressing 
the shHK2#1 compared to those expressing shNS after 3 and 7 days of doxycycline 
administration (Figure 2-13a). To assess the effect of HK2 knockdown on long-term tumor 
growth, mice were given doxycycline or sucrose (control) once tumors reached an average 
volume of 152 mm3 (standard deviation (SD) 46 mm3).  No change in growth was observed in 
the shNS tumors in mice treated with doxycycline, confirming that administration of doxycycline 
alone had no effect on tumor growth (Figure 2-14a). However, induction of shHK2#1 expression 
 
Figure 2-12: Extracellular lactate enhances invasion of PDAC cell lines 
Percent invasion in PDAC cells incubated with extracellular lactate (40 mM). Mean ± SEM of 
biological replicates (n=6) shown with student’s t-tests for statistical significance. 
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resulted in tumor growth inhibition during the 30 day treatment period compared to the shNS 
controls (P<0.030, Figure 2-14b). At the end of treatment an average reduction in tumor volume 
of 57.5% was observed with HK2 knockdown (P=0.020, Figure 2-14b).  
RNA sequencing was performed on tumors harvested at the end of the study to determine 
the effect of HK2 knockdown on gene expression in vivo (Figure 2-13b). Genes whose average 
reads per kilo base of transcript per million mapped reads (RPKM) was <10 were excluded from 
analysis, so that only genes with a high level of baseline expression were included (n=6 120). 
Gene set enrichment analysis (GSEA) was performed to identify differentially regulated gene 
sets between control (shNS, n=3) and HK2 knockdown (shHK2#1, n=4), with a focus on gene 
sets contained in the molecular signature database’s (MSigDBv5) hallmark and oncogenic 
signatures gene lists (Subramanian et al., 2005).  
We found 27 gene sets to be significantly enriched in shNS tumors relative to shHK2 
tumors (P<0.02, false discovery rate (FDR)<0.100, Table 2-1) and 18 gene sets significantly 
enriched with HK2 knockdown relative to shNS (Supplementary table 4, P<0.02, FDR<0.100, 
Table 2-2) (Subramanian et al., 2005). Interestingly, one of the highest enriched pathways in the 
control tumors included genes upregulated with increased vascular endothelial growth factor-A 
(VEGF-A) activity (VEGF_A_UP.VI_UP, normalized enrichment score (NES) 2.2, P<0.001, 
FDR<0.001, Figure 2-15, Figure 2-16), a pathway important for promoting metastasis 
(Schoenfeld et al., 2004, Zetter, 1998).  Furthermore, genes downregulated with VEGF-A 
signaling were enriched in the HK2 knockdown tumors (VEGF_A_UP.VI_DN, NES -2.4, 
P<0.001, FDR<0.001, Figure 2-15, Figure 2-16), suggesting that HK2 knockdown is associated 
with inhibition of VEGF-A signaling (Schoenfeld et al., 2004).  
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Figure 2-13: Expression of HK2 in CFPAC-1-LUC xenografts containing stable 
expression of doxycycline inducible shRNA constructs. 
(a) Expression of HK2 in CFPAC-1-LUC tumors containing doxycycline inducible shNS or 
shHK2#1 treated with sucrose (control) or doxycycline for 3 or 7 days.  
(b) Expression of HK2 in CFPAC-1-LUC tumors containing doxycycline inducible shNS or 
shHK2#1 after 30 days of treatment.  
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Figure 2-14: HK2 is required for PDAC primary tumor growth in vivo.  
(a) Percent tumor volume relative to start of treatment for shNS tumors treated with sucrose 
(black, n=9) or doxycycline (grey, n=10) for 30 days. Average normalized tumor volume and 
SEM shown.  
(b) Percent tumor volume relative to start of treatment for shHK2 tumors treated with sucrose 
(black, n=8) or doxycycline (grey, n=8) for 30 days. Average normalized tumor volume and 
SEM shown with student’s t-tests for statistical significance at each time point.   
(c) Statistical analysis of final tumor volumes for the four treatment groups. ANOVA analysis 
compared all four groups while t-tests compared treatment vs. control for shNS and shHK2#1. 
Each dot represents a single tumor and mean ± SEM shown. Representative images of tumors 
isolated after 30 days of treatment with sucrose or doxycycline.  
P=0.050
P=0.020
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Figure 2-15: Expression of genes regulated by VEGF-A expression in HK2 knockdown 
and control CFAPC-1-LUC xenografts.  
Heat map of the expression of the top 20 ranked genes from the gene lists by Schoenfeld, et 
al, 2004, including HK2 and VEGF-A, for shNS (control) and shHK2#1 (HK2 knockdown) 
tumors isolated at the end of treatment as determined by RNA-sequencing.  
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Figure 2-16: GSEA enrichment plots for VEGF-A signaling 
(a) Enrichment plot for the genes identified by Schoenfield et al (2004) to be upregulated with 
ectopic expression of VEGF-A in human cell lines. This gene list is significantly enriched in 
control tumors relative to HK2 knockdown (p<0.001, FDR<0.001).  
(b) Enrichment plot for the genes identified by Schoenfield et al (2004) to be downregulated 
with ectopic expression of VEGF-A in human cell lines. This gene list is significantly 
enriched in tumors containing HK2 knockdown relative to control (p<0.001, FDR<0.001). 
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Gene List 
# 
genes 
in list 
NES P-value FDR 
HALLMARK_INTERFERON_GAMMA_RESPONSE 133 2.61 P <0.001 0 
HALLMARK_INTERFERON_ALPHA_RESPONSE 86 2.47 P <0.001 0 
IL21_UP.V1_UP 29 2.17 P <0.001 3.11E-04 
VEGF_A_UP.V1_UP 50 2.18 P <0.001 4.15E-04 
KRAS.KIDNEY_UP.V1_DN 27 2.11 P <0.001 0.001 
ALK_DN.V1_DN 31 1.97 P <0.001 0.004 
HALLMARK_IL6_JAK_STAT3_SIGNALING 37 1.98 P <0.001 0.005 
SINGH_KRAS_DEPENDENCY_SIGNATURE_ 17 1.94 P <0.001 0.006 
HALLMARK_COAGULATION 53 1.89 0.002 0.009 
SRC_UP.V1_UP 35 1.82 0.002 0.017 
PKCA_DN.V1_UP 27 1.79 0.000 0.020 
KRAS.LUNG_UP.V1_DN 25 1.77 0.004 0.025 
HALLMARK_P53_PATHWAY 117 1.73 0.000 0.032 
WNT_UP.V1_UP 44 1.73 0.002 0.034 
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 35 1.73 0.006 0.035 
KRAS.300_UP.V1_DN 23 1.74 0.008 0.036 
BRCA1_DN.V1_DN 19 1.70 0.004 0.037 
IL21_UP.V1_DN 22 1.69 0.015 0.038 
HALLMARK_TNFA_SIGNALING_VIA_NFKB 118 1.67 0.002 0.045 
KRAS.BREAST_UP.V1_UP 26 1.60 0.018 0.075 
ATF2_UP.V1_UP 43 1.58 0.019 0.082 
GCNP_SHH_UP_LATE.V1_DN 69 1.54 0.006 0.092 
STK33_SKM_UP 93 1.53 0.012 0.094 
ESC_J1_UP_EARLY.V1_DN 73 1.54 0.014 0.095 
PRC1_BMI_UP.V1_UP 27 1.54 0.033 0.097 
MEL18_DN.V1_DN 53 1.55 0.014 0.097 
IL2_UP.V1_UP 49 1.54 0.016 0.098 
Table 2-1: Gene sets enriched in shNS (n=3) relative to HK2 knockdown tumors (n=4).  
This includes gene sets found to have a P<0.020 and an FDR<0.100. Gene sets analyzed were 
contained in the MSigDBv5 hallmark and oncogenic gene signature lists (Subramanian et al., 
2005). 
45 
 
 
 
Gene List 
# genes 
in list NES P value FDR 
HALLMARK_MYC_TARGETS_V1 195 -2.51 P <0.001 0.000 
HALLMARK_E2F_TARGETS 144 -2.35 P <0.001 0.000 
VEGF_A_UP.V1_DN 108 -2.34 P <0.001 0.000 
HALLMARK_SPERMATOGENESIS 27 -2.30 P <0.001 0.000 
PIGF_UP.V1_UP 93 -2.27 P <0.001 0.000 
GCNP_SHH_UP_LATE.V1_UP 98 -2.14 P <0.001 0.001 
HALLMARK_G2M_CHECKPOINT 131 -2.09 P <0.001 0.001 
CSR_EARLY_UP.V1_UP 90 -1.90 P <0.001 0.007 
ERB2_UP.V1_DN 100 -1.84 P <0.001 0.011 
GCNP_SHH_UP_EARLY.V1_UP 87 -1.74 P <0.001 0.025 
HALLMARK_MTORC1_SIGNALING 168 -1.69 P <0.001 0.032 
TBK1.DF_DN 146 -1.62 P <0.001 0.053 
CORDENONSI_YAP_CONSERVED_SIGNATURE 35 -1.75 0.002 0.025 
HALLMARK_MITOTIC_SPINDLE 100 -1.70 0.002 0.031 
HALLMARK_MYC_TARGETS_V2 42 -1.66 0.004 0.038 
E2F1_UP.V1_UP 90 -1.55 0.006 0.076 
CSR_LATE_UP.V1_UP 109 -1.59 0.010 0.058 
PRC2_EZH2_UP.V1_UP 51 -1.61 0.014 0.053 
Table 2-2: Gene sets enriched in with HK2 knockdown (n=4) relative to shNS (n=3). 
This includes gene sets found to have a P<0.020 and an FDR<0.100. Gene sets analyzed were 
contained in the MSigDBv5 hallmark and oncogenic gene signature lists (Subramanian et al., 
2005). 
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HK2 is required for PDAC metastasis in vivo 
To examine the requirement of HK2 for the promotion of metastasis, a tail vein assay was 
used (Elkin and Vlodavsky, 2001). CFPAC-1-LUC cells containing inducible shRNA constructs 
were treated with doxycycline prior to tail vein injection to induce shRNA expression (Figure 
2-3a). Bioluminescence was used to monitor development of lung metastases and quantify tumor 
growth (Figure 2-17a). The average bioluminescence measured in the lungs of shNS injected 
mice was approximately 100-fold higher than that observed for the shHK2#1 injected mice 
(P=0.001, Figure 2-17b). The presence of metastatic disease was observed in 7 out of 7 mice 
injected with the shNS control compared to 3 out of 9 mice injected with shHK2#1 cells 
(P=0.011, Figure 2-17c). The presence of metastatic tumors was confirmed using hematoxylin 
and eosin (H&E) staining of sectioned lung tissue obtained from mice injected with shNS 
(Figure 2-18, top row). No histological evidence of tumor formation was observed with injection 
of HK2 knockdown cells (Figure 2-18, bottom row). These results show a requirement for HK2 
in the extravasation and survival of cancer cells at distant organ sites, confirming an important 
role for HK2 in promoting metastasis. 
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Figure 2-17: HK2 is required for metastasis in PDAC. 
(a) Bioluminescence of mice injected with CFPAC-1-LUC shNS cells (top row) and cells 
with HK2 knockdown (CFPAC-1-shHK2 #1, bottom row) at the start of the study (column 
one) and at the end of the study (column 3).  
(b) Bioluminescence measured for tumors observed in lungs obtained after autopsy. Each 
point represents luminescence of tumor foci (shNS, n=7 and shHK2, n=3) or an entire lung if 
no foci were observed (shHK2, n=6).  
(c) Fisher’s exact t-test showing a significant difference in formation of metastases with HK2 
knockdown (P=0.011).  
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DISCUSSION 
PDAC is a highly lethal disease with an increased incidence of metastasis and an overall 
poor prognosis (Ryan et al., 2014). Similar to a GEMM which showed genes regulating glucose 
metabolism to be upregulated in PDAC (Ying et al., 2012), we saw increased expression of key 
glycolytic genes, including GLUT1, HK2 and LDHA, in primary PDAC tumors relative to 
normal pancreas, suggesting a role for these genes in human tumorigenesis. We show that 
knockdown of HK2 results in decreased PDAC growth in vitro and in vivo, in agreement with 
 
Figure 2-18: Histological evidence of tumor formation in mice injected with control 
PDAC cell lines (shNS).   
Representative ex vivo images used for quantification of bioluminescence. H&E staining was 
used to confirm metastases formation. Arrowheads point to cancer cells in a metastatic lesion 
with surrounding normal lung tissue (top row). Lungs that did not exhibit bioluminescence 
showed no histological evidence of metastases (bottom row).  
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what has been observed in other cancers (Gershon et al., 2013, Patra et al., 2013, Wolf et al., 
2011, Yoshino et al., 2013). HK2 regulates glucose uptake, a process upstream of metabolic 
pathways including glycolysis, hexosamine biosynthesis, the pentose phosphate pathway and the 
citric acid cycle (Bryant et al., 2014, Ying et al., 2012). Direct targeting of HK2 can, therefore, 
impede the flow of glucose into multiple downstream pathways necessary for KRAS driven 
tumor growth (Daemen et al., 2015, Ying et al., 2012). Genetic deletion of HK2 in a preclinical 
model of Kras driven lung cancer was sufficient to alter glucose metabolism and improve overall 
survival (Patra et al., 2013), suggesting that direct targeting of HK2 would be beneficial in 
PDAC.   
We also show that increased expression of HK2 in primary tumors is associated with 
shorter overall survival in PDAC patients undergoing curative surgery, in agreement with a 
smaller study that correlated increased HK2 protein expression with worse PDAC patient 
outcomes (Ogawa et al., 2015). This, along with the observation that HK2 is upregulated in 
PDAC metastases relative to primary tumors, supports a role for HK2 in the metastatic process. 
Associations between increased HK2 expression, metastatic disease, and poor clinical outcomes 
have been observed in other cancers however a direct link between HK2 and metastasis has not 
been shown (Hamabe et al., 2014, Ogawa et al., 2015, Palmieri et al., 2009).  
Here we provide direct evidence that HK2 is necessary and sufficient to promote 
metastasis in PDAC, as its increased expression promotes invasion and its knockdown inhibits 
cancer cell extravasation and colonization at distant organ sites, important components of the 
metastatic cascade (Lee et al., 2015, Zetter, 1998). A study of PDAC cell lines correlated 
increased rates of glycolysis with aggressive tumor biology, suggesting that glycolysis may be 
important for metastasis (Daemen et al., 2015). We found that HK2 directly promotes metastasis 
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via regulation of glycolysis, as pharmacologic inhibition of lactate production prevents HK2-
driven invasion and extracellular lactate is sufficient to enhance invasion. This result is in 
agreement with previous studies showing extracellular lactate enhances migration of breast 
cancer cell lines, encourages metastases seeding of breast cancer cell lines in vivo and promotes 
motility of glioblastoma cell lines (Baumann et al., 2009, Bonuccelli et al., 2010). As increased 
lactate production has also been linked to poor patient outcomes (Bonuccelli et al., 2010, Brizel 
et al., 2001, Daemen et al., 2015, Xian et al., 2015) we suggest that direct targeting of HK2 or 
inhibition of glycolysis may improve patient outcomes by limiting the formation of metastases.  
Increased rates of glycolysis can promote invasion by altering the pH of the tumor 
microenvironment, enhancing cell signaling, influencing matrix metalloprotease activity and 
regulating gene expression (Baumann et al., 2009, Bonuccelli et al., 2010, Kato et al., 2005, 
Latham et al., 2012, Martinez-Outschoorn et al., 2011, Xu et al., 2002). We show that genes 
involved in VEGF-A signaling, a pathway important for angiogenesis and metastasis (Zetter, 
1998), are significantly altered by HK2 knockdown. While a direct link between HK2 and 
VEGF-A was not assessed here, others have shown that lactate production influences VEGF-A 
signaling (Shi et al., 2001, Sonveaux et al., 2012, Xu et al., 2002). We show that extracellular 
lactate enhances PDAC cell invasion when present at concentrations known to influence gene 
expression (Latham et al., 2012). We hypothesize that HK2 regulates lactate production and this, 
in turn, promotes VEGF-A signaling and changes in gene expression necessary for metastasis. 
While our data supports this hypothesis, more studies are needed to confirm the connection 
between HK2 and VEGF-A.  
In conclusion the present study supports a requirement for HK2 in PDAC tumorigenesis 
and metastasis that helps explain the associated findings of high HK2 expression in PDAC 
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patients with metastatic disease. We show that HK2 influences the invasive potential of PDAC 
cells by directly regulating glycolysis and that its knockdown induces changes in gene 
expression of pathways important for promoting metastasis, including VEGF-A signaling. Our 
data suggests that the targeting of HK2 may be a promising approach for treating metastatic 
disease. 
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MATERIALS AND METHODS 
Cell culture and stable cell line generation 
Human cell lines CFPAC-1, HPAF-II, Hs 766T, T3M4, and PANC-1 were obtained from 
the American Type Culture Collection and authenticated via short–tandem repeat profiling 
(Genetica, Burlington, NC, USA). The HPNE cell line was described previously (Neel et al., 
2014). CFPAC-1 was cultured in RPMI 1640, CFPAC-1-LUC was cultured in RPMI 1640 with 
geneticin (500 µg/mL, Invitrogen, Grand Island, NY, USA), and PANC-1 was cultured in 
DMEM. All were supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 
penicillin/streptomycin (Invitrogen) and incubated at 37 °C in 5% CO2 atmosphere. For HK2 
overexpression, the HK2 cDNA sequence from the pDONR-223-HK2 donor vector (Johannessen 
et al., 2010) (Addgene #23854) was cloned into a pHAGE puro destination vector (donated by 
the laboratory of William Kim, MD) using LR-clonase reaction as per the manufacturer’s 
instructions (ThermoFisher Scientific #11791, Grand Island, NY, USA). For HK2 knockdown 
cell lines, shRNA sequences (below) were cloned into the pTRIPZ plasmid using EcoR1 and 
Xho1 restriction enzyme digestion of the pTRIPZ-shNS vector (donated by the laboratory of 
Channing Der, PhD). All constructs were verified by Sanger sequencing (Eton Biosciences, 
Research Triangle Park, NC, USA).  
shHK2#1: CCGTAACATTCTCATCGATTT 
shHK2#2: GCTACAAATCAAAGACAAGAA 
A replication-incompetent lentivirus was generated in 293T cells using psPAX2 (Gag, 
Pol, Rev, Tat), pMD2.G (VSV-G), and target vector. For transduction, 1×106 cells were seeded in 
100 mm plates with media containing lentivirus and polybrene (8 µg/mL, Invitrogen).  After 24 
hours, infected cells were selected with puromycin (2 µg/mL, Invitrogen). To induce shRNA 
53 
 
expression in pTRIPZ lines, cells were incubated for 72 hours with media containing 2 µg/mL 
doxycycline (Sigma-Aldrich, St. Lois, MO, USA). 
 
Transient knockdown with siRNA 
Reverse transfection in a six-well plate was performed with Lipofectamine RNAiMax 
(Invitrogen) as per the manufacturer’s guidelines. 4-5x105 cells were seeded per well and a final 
concentration of 20 nM siNS (#4404021, ThermoFisher Scientific) or siHK2 (Catalog #S6560, 
Applied Biosystems, Grand Island, NY, USA) was used. Cells were incubated for 48 hours prior 
to use in assay or western blot. 
 
Western blot 
Samples were lysed in 200 μL RIPA buffer (pH 7.4) containing protease inhibitors 
(ThermoFisher Scientific). 20-25 µg protein suspended in SDS loading buffer was run on 10% 
SDS polyacrylamide gels and electro transferred to PVDF membranes. Membranes were blocked 
in 5% milk and incubated with 1:1 000 dilutions of primary antibodies in 5% BSA, including 
anti-HK1 (sc-#46695, Santa Cruz Biotechnology, Dallas, TX, USA), anti-HK2 (Catalog #2867, 
Cell Signaling Technology, Danvers, MA, USA), and the loading controls anti-β-Actin (sc-
#47778, Santa Cruz Biotechnology) and anti-vinculin (Catalog #V9131, Sigma). Membranes 
were incubated with 1: 5000 dilutions of appropriate secondary antibodies in 5% milk 
(ThermoFisher Scientific). Incubations were for 1 hour at room temperature and Clarity Western 
ECL substrate with ChemiDoc XRS+ imaging system (Bio-Rad Laboratories, Hercules, CA, 
USA) were used to detect immunoreactive bands.  
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Anchorage independent growth 
1-2 x104 cells were seeded into a soft agar assay as was previously outlined in Martin et 
al (Martin et al., 2011). Briefly a six well plate was coated with 2 mL of a 0.6% bacto-agar and 
culture medium mixture. 500 µL of a cell and 0.4% bacto-agar mixture was added after 
solidification of the first layer. 300 µL media was added every four days for two-three weeks. If 
cells were treated with doxycycline prior to seeding, administration of media with doxycycline (2 
µg/mL) continued. Colony growth was using Image J software (NIH, Bethesda, Maryland, 
USA). Percent growth was calculated by dividing the number of colonies observed by the 
average number of colonies in the corresponding control. 
 
Transwell invasion 
Uncoated inserts with 8-µm pores (Catalog #82050, Greiner Bio-One, Monroe, NC, 
USA) were coated with 100 µL of a diluted growth factor reduced Matrigel membrane matrix 
(300 µg/mL, ThermoFisher Scientific) and incubated at 37 oC for 2 hours. Coated inserts were 
then placed into a 24 well plate containing 750 µL normal culture media. 1-2 x105 cells were 
suspended in 250 µL media supplemented with 1% FBS and seeded into the upper chamber of 
insert. Cells invaded for 16 hours. Inserts were then cleaned, fixed, and stained with Diff Quik as 
per manufacturer’s instructions (ThermoFisher Scientific). The number of cells invading was 
determined by counting five random fields per insert (counted by a blinded second party). 
Percent invasion was calculated by dividing the total number of cells invaded by the average 
number of cells invaded for the appropriate control. 
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Hexokinase activity and lactate production 
To examine hexokinase activity a colorimetric assay was performed as per 
manufacturer’s instructions (Hexokinase activity kit, Catalog #MAK091, Sigma). Sample 
preparation included lysis of 1x106 cells in assay buffer, with a 1:10 dilution of lysate used in 
assay. A glycolysis cell-based assay was performed to measure l-lactate production as per 
manufacturer’s instructions (Catalog #600450, Caymen Chemical, Ann Arbor, MI, USA). 1x104 
cells in 200 µL were seeded per well in a 96-well plate for 24 hours. 20 µL of medium was 
collected into a new 96 well plate for colorimetric detection. Absorbance at appropriate 
wavelengths was measured with a Synergy 2 microplate reader (BioTek, Winooski, VT, USA).  
Percent hexokinase activity and lactate production were determined by dividing the corrected 
absorbance reading for each replicate by the average corrected absorbance for the appropriate 
control.  
 
Cell proliferation 
To examine cell proliferation, 1x103 cells in 200 µl were plated in quadruplicate into 96-
well plates. After 24, 48, 72, or 96 hours of growth, 50 μl of 5 mg/mL 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) dissolved in PBS was added to each well. After 30 
minutes the mixture was aspirated and 200 µl of dimethyl sulfoxide (DMSO) was added to each 
well and mixed thoroughly. A560nm was measured using a Synergy 2 microplate reader (BioTek). 
For IC50 determination 1x103 cells in 200 µl were plated in quadruplicate into 96-well plates. 
After 24 hours, the medium was replaced with medium containing 75 mM PBS or oxamate (75 
mM to 0.1 mM, Sigma).  After 72 hour incubation, 50 μl MTT was added to each well and 
incubated for 30 minutes. The mixture was aspirated and 200 µl of DMSO was added to each 
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well, mixed thoroughly, and A560 nm was measured using a Synergy 2 microplate reader. The 
IC50 was calculated using GraphPad Prism software (v5, GraphPad Software, INC. La Jolla, 
CA, USA).  
 
Gene Expression 
qPCR: RNA was isolated from CFPAC-1, HPNE, HPAF-II, Hs 766T, T3M4, and PANC-
1 cell pellets using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). 2 µg of RNA was 
used for cDNA synthesis (Applied Biosystems) and 50 ng of RNA was used for real-time PCR 
(Applied Biosystems). Reactions were performed in triplicate on a 384 well plate using standard 
PCR settings on a QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems). HK2 
expression was assessed with HK2 TaqMan qPCR array (Applied Biosystems, Hs00606086_m1) 
while β-actin was assessed with ACTB TaqMan qPCR array (Applied Biosystems, 
Hs01060665_g1). The ΔΔCT method was used for analysis.   
 
RNA sequencing: 200-1000 ng of total RNA was used to prepare libraries with the 
TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA). 75 base pair paired-
end reads were sequenced on a NextSeq 500 Desktop Sequencer using a high output flow cell kit 
(Illumina). Reads were separated by species of origin using Xenome (Conway et al., 2012). 
Human specific reads were then aligned and quantified using Tophat2 (Kim et al., 2013), 
Cufflinks (Trapnell et al., 2012), hg19, mm10, and the UCSC transcript and gene definitions 
(genome.ucsc.edu). mRNA gene expression was analyzed with javaGSEAv2.2.1, and 
MSigDBv5.0 (Subramanian et al., 2005). 
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Animal Studies: All mouse studies were completed under protocols approved by the UNC 
Institutional Animal Care and Use Committee.  
Subcutaneous tumor injection: 2x106 CFPAC-1-LUC shRNA cells were subcutaneously 
injected into the flanks of 6-8 week old female nu/nu mice. When tumors grew to a mean of 152 
mm3 (SD 45.5 mm3) mice were randomized and given either 2.5% sucrose or 2.5% sucrose + 1 
mg/mL doxycycline in drinking water for the specified time period. Tumor volume was 
measured three times per week and calculated using the formula (length×width2)/2. Student’s t-
tests compared the growth of treatment versus control during the study and a one-way ANOVA 
with Bonferroni correction for multiple comparisons test determined statistical significance of 
final tumor volume. 
 
Tail vein injection: CFPAC-1-LUC shNS and CFPAC-1-LUC shHK2#1 cells incubated 
with culture medium containing 2 µg/mL doxycycline for 72 hours prior to injection. Treatment 
continued via administration of a 2.5% sucrose + 1mg/mL doxycycline throughout the study. 
2x106 cells in 100 µL PBS were injected into the tail veins of 6-8 week old female nu/nu mice as 
previously described in Elkin, et al (Elkin and Vlodavsky, 2001). Mice were monitored for lung 
metastases weekly after the initial injection using an IVIS Lumina Kinetic optical imaging 
system with an EMCCD camera (PerkinElmer, Waltham, MA, USA).  Lungs were collected 
upon autopsy, fixed in 10% formalin, paraffin embedded (FFPE), and sectioned into 10 µM 
slices at 100 µM intervals and stained with H&E. Fisher’s exact t-test determined statistical 
significance. 
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CHAPTER 3 : MICRO RNA REGULATION OF TUMOR GROWTH AND 
METASTASIS BY INHIBITION OF HEXOKINASE 2 IN PANCREATIC CANCER2 
 
INTRODUCTION 
In chapter 2, we showed the metabolic enzyme hexokinase 2 (HK2) to be necessary and 
sufficient for promoting tumor growth and metastasis in pancreatic ductal adenocarcinoma 
(PDAC). This ability of HK2 to act as an oncogene in PDAC suggests that is regulation is 
critically important for PDAC disease progression. A variety of mechanisms are known to 
regulate HK2 expression, including hypoxia, low glucose, and oncogenic Kras activity 
(Natsuizaka et al., 2007, Ying et al., 2012). More recently microRNAs (miRNAs) have been 
shown to be important regulators of HK2 (Fang et al., 2012, Jiang et al., 2012, Yoshino et al., 
2013), although their contribution to PDAC tumorigenesis by regulating HK2 has not yet been 
investigated.  
miRNAs are short, non-coding RNA molecules that are endogenously expressed and 
function as negative regulators of gene expression (Bartel and Chen, 2004). miRNAs bind in a 
sequence dependent manner to the 3’ untranslated region (3’UTR) of target mRNAs and this 
interaction results in the recruitment of proteins required for mRNA degradation and/or 
                                                 
2 The concept of this project was developed by myself and Jen Jen Yeh. I completed the in vitro 
experiments found in this chapter, while Jannette Baren-Gale in the laboratory of Praveen 
Sethupathy completed the analysis of miRNA sequencing data.  
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inhibition of translation (Bartel and Chen, 2004, Huntzinger and Izaurralde, 2011). A single 
miRNA has the ability to target many different mRNAs and can regulate multiple biological 
processes important for cell growth and survival, including glucose metabolism (Singh et al., 
2012). miRNAs are of growing interest to the field of cancer research because they are often 
dysregulated in tumor tissue and may be useful for the diagnosis or treatment of cancer (Ruan et 
al., 2009).  
As discussed above, miRNA regulation of HK2 has been shown to be important for 
tumorigenesis. More specifically, miR-143, a miRNA down regulated in Kras-mutant lung 
tumors, inhibits tumor growth in lung cancer by negatively regulating HK2 (Fang et al., 2012). 
As similar regulatory relationship between miR-143 and HK2 has been observed in other cancer 
types, suggesting that miRNA regulation of HK2 is important for inhibiting tumorigenesis (Fang 
et al., 2012, Jiang et al., 2012, Yoshino et al., 2013). While miRNA regulation of HK2 in PDAC 
has not been studied, we hypothesize that it is critically important for inhibiting both primary 
tumor growth and metastasis in PDAC, two processes that require HK2. miRNAs regulating 
HK2 expression in PDAC may also be therapeutically important, as miRNA mimics may 
represent a novel approach to targeting HK2 in the clinic.  
The current study sought to identify novel miRNAs regulating HK2 expression in PDAC. 
We observed miR-148a and miR-216b, miRNAs known to be downregulated in PDAC precursor 
lesions and primary tumors, to be negatively associated with HK2 expression. We showed these 
miRNAs to be important regulators of HK2 expression, anchorage independent growth (AIG), 
and invasion in PDAC cell lines. Our preliminary data supports a potential role for miR-148a and 
miR-216b as tumor suppressors in PDAC by regulating HK2 expression. 
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RESULTS 
Identification of novel miRNAs regulating HK2 in PDAC 
To identify miRNAs that regulate HK2 in PDAC, miRNA and mRNA expression in 58 
primary PDAC tumors and 3 normal, tumor adjacent tissues were examined (the Cancer Genome 
Atlas, http://cancergenome.nih.gov). Because a direct interaction between a miRNA and its 
target mRNA results in decreased levels of target mRNA (Huntzinger and Izaurralde, 2011), we 
looked for miRNAs that are negatively correlated with HK2 expression in PDAC tumors. 
Seventy two miRNAs were negatively correlated with HK2 expression (Pearson correlation<-
0.25, Figure 3-1), suggesting that they may inhibit HK2 in PDAC. To further narrow down the 
list of candidate miRNAs, we examined miRNA expression in PDAC tumor tissue relative to 
normal pancreas. Because HK2 is upregulated in PDAC (Figure 2-1), we looked for miRNAs 
that were downregulated in PDAC tissue relative to normal adjacent tissue. Of the 72 miRNAs 
negatively correlated with HK2, 49 miRNAs were downregulated in PDAC tumors relative to 
normal adjacent tissue (Figure 3-1).  
Target prediction software was used to examine which of the 49 downregulated miRNAs 
were predicted to directly interact with the 3’UTR of HK2, an interaction essential for miRNA 
regulation of a target mRNA (Lewis et al., 2005). To limit the number of false positive miRNA-
mRNA interactions identified, only miRNA-mRNA interactions predicted by at least 2 of 3 
target prediction algorithms used in this analysis were considered to be a “true” prediction. 
TargetScan V6.2 (Agarwal et al., 2015), miRanda (Betel et al., 2008), and miRWalk (Dweep et 
al., 2011) were the three target predication algorithms used. Twenty four of the 49 miRNAs 
examined were predicted to interact with the 3’UTR of HK2 by at least 2 of the 3 algorithms 
(Figure 3-1). The resulting list of candidate miRNAs included those miRNAs which were 
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negatively correlated with HK2, downregulated in PDAC tumor tissue relative to normal 
pancreas, and predicted to interact to the 3’UTR of HK2 (Table 3-1).  
Interestingly miR-143, a miRNA previously shown to be important in regulation of HK2 
in other cancer types was not found to be negatively correlated with HK2 expression and was 
upregulated in patient tumors relative to normal pancreas (Bloomston et al., 2007), suggesting 
that this miRNA may not function as a tumor suppressor by directly regulating HK2 in PDAC. 
Included in the list are two miRNAs, miR-148a and miR-261b, previously shown to be 
diagnostic of PDAC and downregulated in PDAC tumors relative to normal pancreas in larger 
datasets (Bloomston et al., 2007, Schultz et al., 2012, Xue et al., 2013). Downregulation of miR-
148a and miR-216b was an early event in PDAC tumorigenesis (Hanoun et al., 2010, Yu et al., 
2012), further suggesting an important role for these miRNAs in driving PDAC disease 
progression. Because multiple studies showed an association between miR-148a and miR-216b 
and tumor development PDAC, we evaluated these two novel candidate miRNAs for their ability 
to inhibit tumor growth in PDAC by negatively regulating HK2 expression.    
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Figure 3-1: Scheme for identification of novel miRNA regulators of HK2 in PDAC 
miRNA and mRNA expression from the Cancer Genome Atlas dataset for PDAC, which 
contained gene expression from 58 PDAC tumor samples and 3 normal adjacent tumor tissues, 
was used to identify 24 novel candidate miRNAs regulating HK2 expression in PDAC.  
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Stem-loop 
Correlation 
with HK2 
Expression 
Log2 fold 
change 
P value 
for fold 
change 
miRanda miRWalk TargetScan 
hsa-mir-140-3p hsa-mir-140 -0.506 -0.650 0.821 Yes Yes Yes 
hsa-mir-381 hsa-mir-381 -0.492 -0.336 0.803 Yes Yes Yes 
hsa-mir-140-5p hsa-mir-140 -0.438 -1.721 0.035 Yes Yes Yes 
hsa-mir-218-1-5p hsa-mir-218-1 -0.430 -0.839 0.300 Yes Yes Yes 
hsa-mir-218-2-5p hsa-mir-218-2 -0.429 -0.839 0.295 Yes Yes Yes 
hsa-mir-204-5p hsa-mir-204 -0.413 -1.712 0.615 Yes Yes Yes 
hsa-mir-136-5p hsa-mir-136 -0.410 -1.633 0.091 Yes - Yes 
hsa-mir-195-5p hsa-mir-195 -0.370 -1.250 0.345 Yes Yes Yes 
hsa-mir-150-5p hsa-mir-150 -0.354 -2.368 0.445 Yes Yes Yes 
hsa-mir-98 hsa-mir-98 -0.354 -0.166 0.749 Yes Yes Yes 
hsa-mir-30e-5p hsa-mir-30e -0.346 -1.515 0.056 Yes Yes - 
hsa-mir-501-3p hsa-mir-501 -0.337 -1.187 0.126 Yes Yes Yes 
hsa-mir-148a-3p hsa-mir-148a -0.330 -0.413 0.384 Yes Yes Yes 
hsa-mir-199b-3p hsa-mir-199b -0.327 -0.182 0.892 Yes Yes Yes 
hsa-mir-199a-1-3p hsa-mir-199a-1 -0.327 -0.182 0.893 Yes Yes Yes 
hsa-mir-199a-2-3p hsa-mir-199a-2 -0.326 -0.187 0.906 Yes Yes Yes 
hsa-mir-148b-3p hsa-mir-148b -0.314 -0.726 0.130 Yes Yes Yes 
hsa-mir-134 hsa-mir-134 -0.288 -0.584 0.242 Yes - Yes 
hsa-mir-30e-3p hsa-mir-30e -0.278 -1.023 0.137 Yes Yes - 
hsa-mir-216a hsa-mir-216a -0.273 -0.362 0.313 Yes Yes Yes 
hsa-mir-185-5p hsa-mir-185 -0.272 -0.858 0.003 Yes Yes Yes 
hsa-mir-216b hsa-mir-216b -0.272 -1.038 0.212 Yes Yes Yes 
hsa-mir-217 hsa-mir-217 -0.271 -0.476 0.936 Yes - Yes 
hsa-mir-497-5p hsa-mir-497 -0.271 -0.872 0.357 Yes Yes Yes 
Table 3-1: 24 candidate miRNAs that are predicted to interact with the 3’UTR of HK2, 
negatively correlated with HK2 expression, and downregulated in PDAC tumor samples. 
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miR-148a and miR-216b directly interact with the 3’UTR of HK2 
 To determine if miR-148a and miR-216b directly interacted with the 3’UTR of HK2, the 
entire 3’UTR sequence of HK2 was inserted into a luciferase reporter construct. The ability of a 
miRNA to suppress luciferase activity in cells containing this reporter construct suggests a direct 
interaction between a target miRNA and the 3’UTR of HK2. miR-143, a miRNA known to 
directly interact with the 3’UTR of HK2, was used as a positive control and caused a 42.4% 
decrease in luciferase activity (Figure 3-2). Similar results were shown with each candidate 
miRNA, as a 39.4% and 60.6% reduction in luciferase activity was observed with introduction of 
miR-148a and miR-216b, respectively (Figure 3-2). These results show a direct interaction 
between miR-148a and miR-216b with the 3’UTR of HK2.  
 
Figure 3-2: Candidate miRNAs miR-148a and miR-216b directly bind the 3’UTR of HK2. 
Luciferase activity was measured in 293T cells transfected with a luciferase reporter construct 
containing the 3’UTR of HK2 and 10 nM candidate miRNA mimics or a non-specific control 
(miR-NS). The luciferase activity was normalized to that measured for an empty vector control 
which was co-transfected with10 nM candidate miRNA mimic or miR-NS. Mean ± standard 
error of the mean (SEM) for biologic replicates shown (n=6).  
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miR-148a and miR-216b inhibit HK2 expression in PDAC cell lines 
 To determine if candidate miRNAs regulate HK2 expression in PDAC cell lines, miR-
148a and miR-216b mimics were introduced into PDAC cell lines. siRNA targeted against HK2 
(siHK2) and miR-143, a miRNA known to inhibit HK2 expression in other cancer cell lines, 
were also introduced into PDAC cell lines and served as a positive control to which the effects of 
candidate miRNA overexpression could be compared. Both HK2 mRNA and protein expression 
were examined upon introduction of miRNA mimics to determine if candidate miRNA-mRNA 
interactions resulted in either mRNA degradation or inhibition of translation of HK2.  
Transient overexpression of miR-148a resulted in an approximate 30% decrease in HK2 
mRNA expression in both PDAC cell lines examined (P<0.003, Figure 3-3a). This was similar to 
the effect of miR-143 overexpression, suggesting that miR-148a negatively regulates HK2 by 
promoting mRNA degradation in PDAC cell lines. Transient overexpression of miR-216b 
resulted in an approximate 20% and 60% decrease in mRNA expression in the CFPAC-1 and 
PANC-1 cell lines, respectively (P<0.050, Figure 3-3a), supporting the hypothesis that miR-216b 
negatively regulates HK2 by promoting mRNA degradation. Transient introduction of miR-148a 
and miR-216b inhibited HK2 protein expression in the PANC-1 cell line, as their overexpression 
resulted in an approximate 30% and 50% reduction in HK2 protein expression, respectively 
(Figure 3-3b). These results suggest that both miR-148a and miR-216b negatively regulate HK2 
protein expression by promoting mRNA degradation in PDAC cell lines.  
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Figure 3-3: miR-148a and miR-216b inhibit HK2 mRNA and protein expression in PDAC. 
(a) The fold change in expression of HK2 with introduction of siHK2 or candidate miRNA 
mimics relative to the non-specific control (miR-NS). Fold change determined using the ΔΔCT 
method with mean ± SEM shown (n=3 technical replicates). 
(b) Change in HK2 expression after 48 hours of candidate miRNA overexpression in the PANC-
1 cell line. HK2:Actin intensity was determined by densitometry and reported relative to the 
average ratio observed for miR-NS.  
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miR-148a and miR-216b inhibit AIG and invasion of PDAC cell lines 
Since miR-148a and miR-216b inhibit HK2 expression in PDAC cell lines, we 
hypothesize that overexpression of these miRNAs in PDAC cell lines will phenocopy the effects 
of HK2 knockdown on AIG and invasion previously described. To directly assess the effects of 
miR-148a and miR-216b overexpression on AIG in PANC-1, a soft agar assay was used (Figure 
3-4a). For comparison, siRNA targeted against HK2 (siHK2) was used to knockdown HK2 in 
PANC-1. Transient knockdown of HK2 with siRNA resulted in a 90.0% decrease in colony 
growth, consistent with previous results showing a requirement of HK2 for AIG of PDAC cell 
lines (P<0.001, Figure 3-4b). Transient overexpression of miR-148a and miR216b in PANC-1 
resulted in a 77.9% and 38.8% decrease in colony growth on soft agar, respectively, suggesting 
that increased expression of both candidate miRNAs phenocopies the effect of HK2 knockdown 
on AIG in PDAC cell lines (P<0.001, Figure 3-4b).  
To directly examine the effect of miR-148a and miR-216b on PDAC cell invasion, a 
transwell invasion assay was used (Figure 3-5a). For comparison, siHK2 was used to knockdown 
HK2 expression. Consistent with previous results showing a requirement of HK2 for invasion in 
PDAC cell lines, transient HK2 knockdown in PANC-1 caused a 58.7% decrease in invasion 
through a reconstituted matrix (P<0.010, Figure 3-5b). Transient overexpression of miR-148a 
resulted in a 68.0% decrease in invasion in PANC-1, while overexpression of miR-216b caused a 
44.7% decrease in invasion (P<0.040, Figure 3-5b). These results show that candidate miRNA 
overexpression phenocopies HK2 knockdown in PDAC cell lines and that overexpression of 
either miR-148a or miR-216b is sufficient to inhibit invasion.  
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Figure 3-4: miR-148a and miR-216b inhibit AIG of the PANC-1 cell line.   
(a) Representative images of colony formation in soft agar assays.  
(b) Percent of growth with miRNA overexpression (25 nM) relative to control (miR-NS). 
Mean ± SEM of biological replicates shown (n=4).  
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Figure 3-5: miR-148a and miR-216b inhibit invasion of the PANC-1 cell line.   
(a) Representative images of invasion from transwell invasion assay  
(b) Percent of growth with miRNA overexpression (25 nM) relative to control (miR-NS). 
Mean ± SEM of biological replicates shown (n=3).  
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DISCUSSION 
PDAC is a highly lethal disease with an increased incidence of metastases and overall 
poor prognosis (Ryan et al., 2014). We have previously shown that HK2 is an important driver of 
tumor growth and metastasis in PDAC and that inhibition of HK2 would be a good strategy for 
the treatment of advanced PDAC. While there are no pharmacologic inhibitors of HK2 currently 
available, others have found miRNAs to be useful inhibitors of HK2 expression in preclinical 
cancer models (Fang et al., 2012, Jiang et al., 2012, Yoshino et al., 2013). Analysis of miRNA 
and mRNA expression identified 24 novel miRNAs which are negatively correlated with HK2 
expression in PDAC, downregulated in PDAC tumors relative to normal pancreas, and predicted 
to bind the 3’UTR of HK2.  Importantly miR-143, a miRNA previously shown to be important 
for regulation of HK2 in other cancer types, was not included in this list of candidate miRNAs, 
suggesting that other miRNAs may play an important role in regulation of HK2 in PDAC.  
miR-148a and miR-216b, two miRNAs known to be downregulated in PDAC precursor 
lesion and tumors, were included in the list of potential miRNAs regulating HK2 in PDAC 
(Bloomston et al., 2007, Hanoun et al., 2010, Yu et al., 2012). We show that miR-148a and miR-
216b may function as tumor suppressors in PDAC by directly inhibiting HK2 expression, as 
transient overexpression of these miRNAs is sufficient to decrease HK2 mRNA, AIG, and 
invasion in PDAC cell lines. The importance of miR-148a and miR-216b for regulation of HK2 
expression has not been previously shown, but it is known that these two miRNAs function as 
tumor suppressors in other cancer types. miR-148a suppresses invasion in hepatocellular 
carcinoma by inhibiting the epithelial to mesenchymal transition (Zhang et al., 2013) while miR-
216b decreases invasion of KRAS-mutant cancer cell lines by negatively inhibiting oncogenic 
KRAS activity and its downstream signaling pathways (Deng et al., 2011).  
71 
 
It is clear that miR-148a and miR-216b have the potential to regulate many different 
pathways important for oncogenesis, but our data suggests that miR-148a and miR-216b 
regulation of HK2 may be especially important for inhibiting PDAC tumor growth and 
metastasis.  Delivery of miRNA mimics and inhibitors is currently under investigation in 
preclinical models of cancer and include systemic delivery of modified nucleic acids or direct 
targeting of miRNAs to tumor tissue with nanoparticles (Price and Chen, 2014). Both of these 
strategies maybe feasible for the treatment of advanced PDAC, as systemic inhibition of HK2 in 
a GEMM causes no systemic defects in glucose tolerance and does not decrease growth or 
overall survival (Patra et al., 2013). Because miRNAs target many different mRNAs at once, it 
seems likely that systemic delivery of miR-148a and miR-216b mimics may cause off-target 
effects that may not be observed with direct pharmacologic inhibition of HK2. Thus, directed 
delivery of miRNAs to tumor tissue may be more clinically useful. 
Our work outlines a potential role for miR-148a and miR-216b as tumor suppressors in 
PDAC by directly inhibiting the expression of HK2, a protein required for increased glycolysis, 
tumor growth and invasion of PDAC cell lines. More studies, however, are needed to verify the 
role of miR-148a and miR-216b as tumor suppressors in PDAC.  
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MATERIALS AND METHODS 
Cell culture and plasmid generation 
The human cell lines HEK293T, CFPAC-1, and PANC-1 were obtained from the 
American Type Culture Collection and authenticated via short–tandem repeat profiling 
(Genetica, Burlington, NC, USA). CFPAC-1 was cultured in RPMI 1640 while HEK293T and 
PANC-1 were cultured in DMEM. All media was supplemented with 10% fetal bovine serum 
(FBS, Invitrogen) and penicillin/streptomycin (Invitrogen) and incubated at 37 °C in 5% CO2 
atmosphere. For luciferase reporter constructs, the primers listed below were used to amplify the 
3’UTR of HK2 from CFPAC-1 genomic DNA. Overnight Xho1 restriction enzyme digestion of 
the pPSI-CHECK2 vector was used to linearize plasmid DNA prior to ligation (donated by the 
laboratory of Al Baldwin, PhD). Ligation of the HK2 3’UTR PCR fragment and pPSI-CHECK2 
vector was performed using the In-Fusion HD cloning system as per the manufacturer’s 
instructions (Clontech, Mountain View, CA, USA). The final construct were verified by Sanger 
sequencing (Eton Biosciences, Research Triangle Park, NC, USA).  
HK2 3’UTR US: TAGGCGATCGCTCGAAACCCCTGAAATCGGAAGG 
HK2 3’UTR DS: AATTCCCGGGCTCGAAACATCTTCACTAGACTGAG 
 
Luciferase binding assay 
1x104 HEK293T cells were plated in each well of a 24 well plate. After 24 hours 100 ng 
vector DNA and 10nM miRNA mimics were co-transfected into HEK293T cells using 
Lipofectamine 2000 (Invitrogen). miRNA mimics were transfected with either an empty vector 
control or a vector containing the 3’UTR of HK2. 24 hours post transfection the cells were 
trypsinized and pelleted. Cells were suspended in 100 µL of PBS, lysed in 100 µL of the dual-
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glo® luciferase reporter assay lysis buffer as per manufacturer’s instructions, and the entire 
reaction was placed in a 96 well plate (Promega, Madison, WI, USA). Firefly luciferase activity 
was measured with a Synergy 2 microplate reader (BioTek, Winooski, VT, USA). 100 µL stop 
solution was added per well, incubated for 5 minutes, and renilla luciferase activity with the 
Synergy 2 microplate reader. The renilla luciferase activity, which varies with the interaction 
between a miRNA and the 3’UTR sequence, was normalized to firefly luciferase activity, which 
served as a transfection control for each biological replicate (n=6). The renilla:firefly luciferase 
activity for the construct containing the 3’UTR relative to the empty vector was determined for 
each miRNA and the ratio of 3’UTR:Emtpy vector for each candidate miRNA was normalized to 
that obtained for the miRNA negative control for each biological replicate (miR-NS).  
 
Expression of siRNA or miRNA mimics 
Reverse transfection in a six-well plate was performed with Lipofectamine RNAiMax 
(Invitrogen) as per the manufacturer’s guidelines. 4-5x105 cells were seeded per well and a final 
concentration of 25 nM mirVANA mimic Negative Control #1 (miR-NS, Catalog #4464058, 
Ambion, Grand Island, NY, USA ), siHK2 (Catalog #S6560, Applied Biosystems, Grand Island, 
NY, USA), miR-148a mirVANA mimic (Catalog #MC10263, Applied Biosystems) or miR-216b 
mirVANA mimic (Catalog #MC12302, Applied Biosystems) was used. Cells were incubated for 
48 hours prior to use in assay or western blot. 
 
Western blot 
Samples were lysed in 200 μL RIPA buffer (pH 7.4) containing protease inhibitors 
(ThermoFisher Scientific). 20-25 µg protein suspended in SDS loading buffer was run on 10% 
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SDS polyacrylamide gels and electro transferred to PVDF membranes. Membranes were blocked 
in 5% milk and incubated with 1:1 000 dilutions of primary antibodies in 5% BSA, including 
anti-HK2 (Catalog #2867, Cell Signaling Technology, Danvers, MA, USA) and the loading 
control anti-β-Actin (sc-#47778, Santa Cruz Biotechnology). Membranes were incubated with 1: 
5000 dilutions of appropriate secondary antibodies in 5% milk (ThermoFisher Scientific). 
Incubations were for 1 hour at room temperature and Clarity Western ECL substrate with 
ChemiDoc XRS+ imaging system (Bio-Rad Laboratories, Hercules, CA, USA) were used to 
detect immunoreactive bands.  
 
Quantitative PCR (qPCR) 
RNA was isolated from CFPAC-1 and PANC-1 cell lines 48 hours after introduction of 
siRNA or miRNA using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). 2 µg of RNA 
was used for cDNA synthesis (Applied Biosystems) and 50 ng of RNA was used for real-time 
PCR (Applied Biosystems). Reactions were performed in triplicate on a 384 well plate using 
standard PCR settings on a QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems). 
HK2 expression was assessed with HK2 TaqMan qPCR array (Applied Biosystems, 
Hs00606086_m1) while β-actin was assessed with ACTB TaqMan qPCR array (Applied 
Biosystems, Hs01060665_g1). The ΔΔCT method was used for analysis.   
 
Anchorage independent growth 
1-2 x104 cells were seeded into a soft agar assay after 48 hours of siRNA or miRNA 
overexpression as was previously outlined in Martin et al (Martin et al., 2011). Briefly a six well 
plate was coated with 2 mL of a 0.6% bacto-agar and culture medium mixture. 500 µL of a cell 
75 
 
and 0.4% bacto-agar mixture was added after solidification of the first layer. 300 µL media was 
added every four days for two-three weeks. Colony growth was quantified using Image J 
software (NIH, Bethesda, Maryland, USA). Percent growth was calculated by dividing the 
number of colonies for each biological replicate (n=4) observed by the average number of 
colonies in the control. 
 
Transwell invasion 
Uncoated inserts with 8-µm pores (Catalog #82050, Greiner Bio-One, Monroe, NC, 
USA) were coated with 100 µL of a diluted growth factor reduced Matrigel membrane matrix 
(300 µg/mL, ThermoFisher Scientific) and incubated at 37 oC for 2 hours. Coated inserts were 
then placed into a 24 well plate containing 750 µL normal culture media. 48 hours after 
introduction of siRNA or miRNA, 1-2 x105 cells were suspended in 250 µL media supplemented 
with 1% FBS and seeded into the upper chamber of insert. Cells invaded for 16 hours. Inserts 
were then cleaned, fixed, and stained with Diff Quik as per manufacturer’s instructions 
(ThermoFisher Scientific). The number of cells invading for each biological replicate (n=3) was 
determined by counting five random fields per insert. Percent invasion was calculated by 
dividing the total number of cells invaded by the average number of cells invaded for the 
appropriate control 
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CHAPTER 4 : DISCUSSION AND FUTURE DIRECTIONS 
 
DISCUSSION 
Clinical relevance 
Pancreatic cancer, over 85% of which is pancreatic ductal adenocarcinoma (PDAC), is a 
highly lethal malignancy with an increased incidence of metastasis and an overall poor prognosis 
(Howlader et al., 2013, Ryan et al., 2014). Metastatic PDAC patients are not considered 
candidates for curative surgery and their treatment is limited to cytotoxic chemotherapies, many 
of which produce modest, if any, response (Ryan et al., 2014). Many preclinical studies have 
focused on understanding pathways important for promoting tumor growth and metastasis in 
PDAC, with the hope that targeted therapies will improve clinical outcomes in metastatic PDAC. 
Over 95% of PDAC patient tumors contain activating mutations in the oncogene KRAS (Cox et 
al., 2014). Oncogenic KRAS mutations are sufficient to drive tumor growth in preclinical mouse 
models of PDAC, suggesting that activation of this signaling pathway is particularly important 
for driving disease progression (Guerra and Barbacid, 2013). Oncogenic Kras promotes 
increased glucose uptake, transcriptional upregulation of enzymes responsible for anabolic 
glucose metabolism and PDAC tumor maintenance (Ying et al., 2012). Genetic and 
pharmacologic inhibition of pathways involved with glucose metabolism decreases PDAC tumor 
growth (Daemen et al., 2015, Ying et al., 2012), suggesting that targeting glucose uptake may be 
therapeutically important in PDAC.   
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We show that genetic inhibition of HK2 results in decreased PDAC glycolysis, tumor 
growth and metastasis, suggesting that HK2 is an important driver of disease progression in 
PDAC. While a pharmacologic inhibitor of HK2 has not been tested in preclinical models, 
genetic inhibition of HK2 expression in an adult GEMM does not cause overt defects in glucose 
metabolism, weight loss, or decreased overall survival (Patra et al., 2013). This provides strong 
evidence that systemic targeting of HK2 may be well tolerated in the clinic and may be a good 
option in advanced PDAC.  
 
HK2 drives tumor growth in PDAC 
The importance of HK2 for in Kras-driven tumor growth was first shown in lung cancer 
GEMM, where genetic deletion of HK2 in Kras mutant lung cancer cells causes decreased tumor 
growth and an increase in overall survival (Patra et al., 2013).  Prior to our study, the role of 
HK2 in driving tumor growth in PDAC was unknown. We have built upon existing literature by 
outlining an important role for HK2 in PDAC and showing that inhibition of HK2 is sufficient to 
decrease PDAC tumor growth. We also show that increased levels of HK2 are sufficient to 
promote anchorage independent growth (AIG) and invasion of PDAC cell lines, suggesting that 
HK2 functions as an oncogene in PDAC. This oncogenic activity has not been directly observed 
in the literature and suggests an important role for regulation of HK2 during PDAC oncogenesis.  
PDAC is a molecularly diverse cancer with at least two subtypes that are associated with 
clinical outcomes (Collisson et al., 2011). It is clear that glucose metabolism differs between 
PDAC subtypes and each subtype has different sensitivities to metabolic inhibitors. The classical 
subtype is sensitive to inhibitors of lipid synthesis while the quasi-mesenchymal (QM) subtype is 
sensitive to inhibitors of glycolytic activity. We hypothesize that targeting of HK2 would be an 
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efficient way to treat the multiple subtypes of PDAC as direct inhibition of HK2 can reduce the 
flux of glucose into multiple pathways required for tumor growth in each of the two clinically 
important PDAC subtypes. Future studies should examine the effect of HK2 inhibition in both 
subtypes.  
miRNAs are known to regulate HK2 expression in multiple cancer types and this 
regulation is important for inhibiting tumor growth in preclinical cancer models (Fang et al., 
2012, Gregersen et al., 2012, Jiang et al., 2012). miR-143 functions as a tumor suppressor by 
regulating aerobic glycolysis via targeting HK2 (Fang et al., 2012, Jiang et al., 2012, Yoshino et 
al., 2013), however miR-143 is unlikely to function as a tumor suppressor in PDAC because it is 
upregulated in PDAC tumors relative to normal pancreas (Bloomston et al., 2007, Schultz et al., 
2012). We identified two novel candidate miRNAs, miR-148a and miR-216b, that are negatively 
correlated with HK2 expression in PDAC, directly interact with the 3’UTR of HK2, inhibit HK2 
mRNA expression, and AIG of PDAC cell lines. Decreased expression of each of these 
candidate miRNAs occurs in PDAC precursor lesions and tumor tissue (Xue et al., 2013, Yu et 
al., 2012), suggesting that their dysregulation contributes to oncogenesis. Our data shows that 
down regulation of miR-148a and miR-216b in PDAC precursor lesions may drive PDAC 
disease progression by regulating HK2 expression. Further studies are needed to confirm the 
tumor suppressive function of miR-148a and miR-216b, but the identification of these miRNAs 
as novel regulators of HK2 may provide new mechanisms for inhibition of HK2 in the clinic.  
 
HK2 promotes metastasis by regulating glycolysis 
Multiple studies have observed increased expression of HK2 in PDAC metastases 
(Chaika et al., 2012, Hamabe et al., 2014, Palmieri et al., 2009), suggesting an association 
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between increased HK2 activity and metastasis. We show that HK2 is required for PDAC cell 
invasion, extravasation, survival, and growth in distant organs. Overexpression of HK2 is 
sufficient to promote invasion of PDAC cell lines, suggesting that proper regulation of HK2 
expression is important for inhibiting disease progression. Overexpression of miRNAs regulating 
HK2 in PDAC cell lines was sufficient to inhibit invasion, further supporting a role for miR-148a 
and miR-216b as tumor suppressors via their regulation of HK2.  
We show that HK2 promotes invasion of PDAC cell lines by increasing glycolysis. 
Addition of the glycolytic inhibitor oxamate abrogated the effects of HK2 overexpression on 
invasion. Although an association between elevated rates of glycolysis and PDAC metastases has 
been shown (Chaika et al., 2012, Daemen et al., 2015), a direct relationship between these two 
has not been previously observed in PDAC. We, therefore, outline an important mechanistic link 
between elevated lactate production and cancer cell invasion. Given this, we hypothesize that 
inhibition of lactate production can prevent formation of metastases. Consistent with this, genetic 
and pharmacologic inhibition of lactate production via targeting of lactate-dehydrogenase A 
(LDHA) inhibits disease progression and metastasis in multiple preclinical models of cancer 
(Sheng et al., 2012, Xian et al., 2015). Future studies will be needed to determine if inhibition of 
lactate production is sufficient to prevent formation of PDAC metastases in vivo.  
 Elevated extracellular lactate can promote metastasis by multiple mechanisms, including 
influencing gene expression and altering the activity of enzymes important for matrix 
degradation (Baumann et al., 2009, Latham et al., 2012, Martinez-Outschoorn et al., 2011, Payen 
et al., 2015). While the effects of lactate production on gene expression or matrix degradation 
were not directly assessed here, we showed that knockdown of HK2 expression in PDAC cell 
line xenografts causes changes in gene expression. More specifically, we show vascular 
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endothelial growth factor A (VEGF-A) signaling to be altered with HK2 knockdown, suggesting 
that lactate-induced changes in gene expression may be at work in PDAC. Because activation of 
VEGF-A signaling occurs with an acidic extracellular pH (Xu et al., 2002), it is possible that 
HK2 knockdown in PDAC xenografts influences the pH of the tumor microenvironment and 
alters VEGF-A signaling by this mechanism. Future studies should directly assess exactly how 
the HK2-driven changes in lactate production influence metastatic potential in PDAC cell lines. 
 
FUTURE DIRECTIONS 
Targeting glucose metabolism in advanced PDAC 
Our studies show that HK2 is both necessary and sufficient to promote primary tumor 
growth and metastasis in PDAC by regulating glycolysis. Direct inhibition of HK2 may be the 
most promising approach to treating PDAC, a disease that requires glucose for various metabolic 
processes including lipid synthesis, nucleotide synthesis, and protein glycosylation (Figure 1-2). 
While we hypothesize that HK2 would eliminate the need to target individual pathways required 
for PDAC tumorigenesis, we have yet to directly test this in vitro. Experiments examining the 
sensitivity of classical and QM PDAC cell lines to genetic inhibition of HK2 should be 
performed. To provide more insight into the metabolic consequences of HK2 inhibition in 
PDAC, future experiments could use carbon isotope labeling to examine how genetic inhibition 
of HK2 influences both glucose and glutamine metabolism in PDAC cell lines representing both 
subtypes. This experiment may be particularly useful in identifying additional metabolic 
pathways important for PDAC cell growth if it is found that the QM subtype is resistant to 
inhibition of HK2.   
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While there are currently no pharmacologic inhibitors of HK2 available, inhibitors of 
lactate production have been successfully utilized in preclinical cancer models to inhibit primary 
tumor growth (Granchi et al., 2014). Future studies could examine the ability of glycolytic 
inhibitors, including the well-tolerated LDHA inhibitor FX-11 (Le et al., 2010), to inhibit 
primary tumor growth and metastasis in a PDAC GEMM. Our results suggest that inhibiting 
glycolysis would limit both primary tumor growth and the development of metastases in this 
model. Inhibitors of glucose uptake, such as 3-bromopyruvate (3-BP) have been examined in 
preclinical models of cancer (Pedersen, 2012), but their efficacy for the treatment of advanced 
PDAC is unknown. Future studies could also examine the ability of 3-BP to inhibit primary 
tumor growth and metastasis in PDAC GEMMs.  
 
Investigating the link between lactate and PDAC metastasis 
While we showed that HK2 influences metastasis by regulating lactate production, we 
did not directly assess how lactate itself influences metastatic potential. Lactate can influence 
gene expression by regulating histone deacetylase activity in cancer cell lines (Latham et al., 
2012). We hypothesized that the changes in gene expression that occurred with HK2 knockdown 
in PDAC cell line xenografts resulted from a change in lactate production and histone 
deacetylase activity. To directly examine this, histone acetylation in tumor cell lysates could be 
examined. If the mechanism described by Lathem et al., occurred in PDAC xenografts, control 
tumor lysates would show increased histone acetylation, as a result of increased lactate levels, 
when compared to tumors with HK2 knockdown. To compare lactate production in tumors with 
and without HK2 knockdown, a mass spectroscopy approach could be used to directly measure 
accumulation of this metabolite in the tumor.  
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To further assess if lactate accumulation influences gene expression in PDAC cell lines, 
RNA sequencing of cell lines after incubation with the glycolytic inhibitor, oxamate, could be 
performed. Changes in gene expression here should be similar to those observed in tumors with 
HK2 knockdown. Histone acetylation status in PDAC cell lines after incubation with 
extracellular lactate or treatment with oxamate would also provide support for the mechanism 
outlined by Latham, et al. 
Extracellular lactate accumulation influences local pH and can, therefore, result in 
activation of signaling pathways required for metastasis, including VEGF-A. Since VEGF-A 
signaling was altered with HK2 knockdown, it is possible that HK2 influences VEGF-A 
expression via a pH-dependent mechanism. While we examined lactate production in PDAC cell 
lines with HK2 knockdown and overexpression, we did not directly examine if changes in HK2 
expression influence extracellular pH. This important relationship could be examined using an 
assay which directly measures the extracellular acidification rate (ECAR) with HK2 knockdown 
and overexpression. Changes in ECAR with HK2 expression would provide evidence for a 
mechanism in which HK2 influences VEGF-A signaling via alteration of extracellular pH. To 
further test if this mechanism is important for PDAC, the relationship between cell culture pH 
and VEGF-A signaling could be examined in PDAC cell lines. An acidic pH is predicted to 
activate VEGF-A signaling, and we would predict similar changes in VEGF-A signaling with 
stable overexpression of HK2. Concordance between changes in VEGF-A signaling with an 
acidic pH and HK2 overexpression would suggest this mechanism is important for driving 
metastasis in PDAC.  
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Exploring miRNA regulation of HK2 in PDAC 
The studies presented in chapter 3 provide preliminary evidence that miR-148a and miR-
216b function as tumor suppressors in PDAC by negatively regulating HK2. Multiple studies 
must be performed to provide stronger evidence supporting a direct relationship between these 
candidate miRNAs and HK2. First, mutagenesis of the 3’UTR of HK2 at the predicted miRNA 
binding sites should be performed to confirm that decrease in luciferase activity observed with 
candidate miRNAs results from direct binding of a miRNA to a specific target sequence. While 
we examined the effects of miR-148a and miR-216b overexpression on HK2 expression in 
PDAC cell lines, hexokinase activity and lactate production in PDAC cell lines with miR-148a 
and miR-216b overexpression should also be examined. This would confirm that overexpression 
of miR-148a and miR-216b is sufficient to inhibit both the expression and activity of HK2 in 
PDAC cell lines. 
Introduction of miR-148a and miR-216b inhibitors could be used to determine if 
inhibition of endogenous miRNA activity results in increased HK2 expression. A moderate to 
high level of baseline miRNA expression is needed for this experiment to be successful. Analysis 
of miRNA expression in PDAC tumors from chapter 3 suggests that while miR-148a is 
expressed in PDAC samples, miR-216b has a relatively low level of baseline expression in 
PDAC tumors. Given this, baseline miRNA expression should be taken into consideration when 
interpreting the effects of miR-216b inhibition on HK2 expression in PDAC cell lines. An 
alternative approach to inhibition of endogenous miRNA activity includes stable overexpression 
of the 3’UTR of HK2. Stable overexpression of the 3’UTR of HK2 would act as an endogenous 
miRNA “sponge” and effectively inhibit miRNAs from negatively regulating endogenous HK2 
mRNA targets. This experiment is less desirable because it does not show which candidates are 
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directly responsible for regulating HK2 and only suggests that mature miRNAs are important for 
regulating HK2 expression in PDAC.  
We showed that overexpression of miR-148a and miR-216b phenocopies HK2 
knockdown, as it inhibited AIG and invasion of PDAC cell lines. While we suggest that miR-
148a and miR-216b function as tumor suppressors by directly inhibiting HK2, our initial studies 
have not ruled out the possibility that these candidate miRNAs inhibit AIG and invasion of by 
targeting additional mRNAs required for these processes. To ensure that the effects of miR-148a 
and miR-216b overexpression on AIG and invasion are specific to their regulation of HK2, 
overexpression of the HK2 cDNA could be introduced into cells along with miRNA mimics. If 
HK2 cDNA abrogates the effects of miR-148a and miR-216b overexpression on AIG and 
invasion, it would be reasonable to conclude that these candidate miRNAs function as tumor 
suppressors by regulating HK2 expression in PDAC.  
 miR-148a and miR-216b are downregulated in PDAC tumors and precursor lesions, 
however the exact mechanism regarding their dysregulation in PDAC has not been investigated. 
One potential mechanism is that oncogenic KRAS activity, a process that occurs in early 
precursor lesions, suppresses the expression of miR-148a and miR-216b in PDAC (Guerra and 
Barbacid, 2013). This can be directly examined using genetic or pharmacologic inhibition of 
oncogenic KRAS in PDAC cell lines and measuring the resulting miRNA expression. If 
oncogenic KRAS activity downregulates miR-148a and miR-216b, then miRNA expression 
would increase upon KRAS inhibition. This experiment may provide new insights into how 
oncogenic KRAS activity promotes tumor formation in PDAC.  
 
85 
 
CONCLUDING REMARKS 
PDAC is a devastating disease with a high incidence of metastasis. We show that HK2 is 
both necessary and sufficient for primary tumor growth and metastasis, suggesting that HK2 
functions as an oncogene and regulators of HK2 are critically important for inhibiting PDAC 
disease progression. miRNAs are negative regulators of gene expression and may, therefore, 
function as tumor suppressors in PDAC by inhibiting HK2. We identified miR-148a and miR-
216b as regulators of HK2 and miRNA overexpression mimics the effect of HK2 knockdown on 
PDAC cell growth and invasion. Identification of miRNA regulators of HK2 provides new 
insights into how HK2 becomes dysregulated during PDAC tumor growth and metastasis. 
miRNAs also represent a novel mechanism to inhibit HK2 in PDAC that may prove useful in the 
clinic for the treatment of advanced disease.   
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